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1 Introduction 
Cancer is a key public health concern accounting for more than seven million 
deaths worldwide in 2008 (Ferlay et al., 2010; IARC, 2008; Thun et al., 2009). It arises 
from a single cell after a transformation process, which results from genetic mutations in 
protooncogenes or tumour suppressor genes that lead to uncontrolled cell proliferation 
(Baumann et al., 2008; Burkhart & Sage, 2008; Finlay et al., 1989; Hahn & Weinberg, 
2002; Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011; Jacks & Weinberg, 2002; 
Karnoub & Weinberg, 2008; Lodish et al., 2000b; Lu et al., 2012; Vogelstein & Kinzler, 
2004). 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type 
of cancer worldwide with an incidence of more than half a million new cases annually 
(Parkin et al., 2005; Vokes et al., 1993; Wilken et al., 2011). Early stages of HNSCC 
(stage I and stage II) have high cure rates. However, at advanced stages (stage III and 
IV), the local tumour control and survival rates decrease dramatically (Parker et al., 1997). 
Due to their inconspicuous location, many cases of HNSCC are discovered at a later 
stage (Wilken et al., 2011). Despite continuing research and advances in conventional 
therapies the overall survival rates for HNSCC had only marginal improvement in the last 
several decades with an overall five year survival rate of as low as 50% (Arbes et al., 
1999; Argiris et al., 2004; Forastiere et al., 2001; Stell, 1989; Vokes et al., 1993; Wilken et 
al., 2011). As a result, there is a significant interest in developing potential alternative and 
less toxic therapies for head and neck cancer to reduce the side effects and toxicity and to 
achieve better clinical outcome (Wilken et al., 2011). 
The classical cancer treatment regimes include surgery, radiotherapy and 
chemotherapy. Radiotherapeutic treatment uses photons and electrons to cure patients or 
control tumour growth (Lawrence et al., 2008). It is estimated that 50% of cancer patients 
receive radiotherapy that contributes to 40% of curative treatment (Deutsche Krebshilfe; 
Baskar et al., 2012; Eke et al., 2010). The functional consequences of irradiation include 
cell killing, deoxyribonucleic acid (DNA) damage and repair, cell cycle alterations, altered 
gene transcription and genomic instability (Baumann et al., 2008). Among these 
consequences, induction of cancer cell death is the main goal of radiotherapy (Baskar et 
al., 2012; Baumann et al., 2008). Several ways, such as mitotic catastrophe, apoptosis, 
necrosis, senescence and autophagy, contribute to the elimination of cancer cells after 
irradiation (Baumann et al., 2008; Chary & Jain, 1989; de Bruin & Medema, 2008; Dewey 
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et al., 1995; Padera et al., 2004; Roninson et al., 2001; Vakifahmetoglu et al., 2008). Cell 
death via mitotic catastrophe is the most important effect of ionising radiation in solid 
tumours (Baumann et al., 2008; Dewey et al., 1995; Hedman, 2012). 
The combination of radiotherapy with cytotoxic chemotherapeutic agents is widely 
used to improve the curative rates of radiotherapy (McGinn et al., 1996; Stratford, 1992). 
As chemotherapeutic agents do not differentiate between tumour tissues and normal 
tissues, the improvement of curative rates using the combined radio-chemotherapeutic 
regime is limited by the cytotoxicity of the chemotherapeutic agents to normal tissues 
(Wachsberger et al., 2003). Therefore, identification of suitable targets to specifically treat 
cancer cells is necessary to minimise the normal tissue damage and to improve the 
therapeutic outcome. 
Interestingly, the radiosensitivity of cells varies according to the cell cycle phases 
(Choy et al., 2008; Sinclair, 1968; Sinclair & Morton, 1963; Terasima & Tolmach, 1963; 
Watanabe & Horikawa, 1980). Radiation-induced DNA damage activates cell cycle 
checkpoints to arrest cell cycle progression (Harrison & Haber, 2006; Melo & Toczyski, 
2002; Sancar et al., 2004; Weitzman et al., 2013). This provides enough time for DNA 
damage repair and prevents replication and segregation of the damaged genome 
(Weinert et al., 1994; Weitzman et al., 2013; Yata & Esashi, 2009). Therefore, 
manipulating the cell cycle by targeting cell cycle regulators, such as cyclin-dependent 
kinases (CDKs), might assist cancer treatment optimisation (Canavese et al., 2012; Diaz-
Padilla et al., 2009; Malumbres et al., 2008). 
CDKs are a group of serine/threonine protein kinases and are involved in 
regulating cell cycle progression, DNA damage response and transcription (Aleem & 
Kaldis, 2006; Wohlbold & Fisher, 2009). The critical role for CDKs in several cellular 
functions and frequent aberrations of their activity in cancer encouraged an intensive 
screening for small-molecule CDK pharmacological inhibitors to block the CDK activity 
(Canavese et al., 2012; Diaz-Padilla et al., 2009; Malumbres et al., 2008). Despite 
intensive research on CDKs as potential anticancer targets, studies evaluating targeting of 
CDKs in combination with irradiation are rare and the specific contribution of CDKs as 
adjuvant targets for radiotherapy remains poorly understood. A key question to be 
answered is which CDK or group of CDKs is a suitable target to attenuate the cellular 
radiosensitivity of cancer cells. 
This study evaluated the role of CDK2 and CDK9 as targets to disturb the 
response of HNSCC cells to ionising radiation. The choice of CDK2 as a target is based 
on its vital role in cell cycling and DNA damage repair (Satyanarayana & Kaldis, 2009a) as 
well as unpublished preliminary data generated by Prof. Cordes and Prof. Aleem 
(Alexandria University, Egypt) show that mouse embryonic fibroblasts knockout for CDK2 
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(CDK2-/- MEFs) are more sensitive to ionising radiation as compared to wild type mouse 
embryonic fibroblasts (WT MEFs). CDK9 was chosen as recent reports suggested that it 
is involved in maintaining the genomic integrity (Yu & Cortez, 2011; Yu et al., 2010). 
The hypothesis of this work was that human HNSCC cells are radiosensitised by 
inhibition of CDK2 or CDK9. We were able to confirm this hypothesis by taken into 
account cell line- as well as growth condition-dependent differences. 
Hence, the results of this study are of considerable importance in understanding 
the molecular mechanisms of the radiation-induced cell cycle response and the possible 
role of CDK2 and CDK9 in this process. This knowledge might assist the improvement of 
a targeted therapy for treating HNSCC. 
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2 Background 
2.1 Cell Cycle as a Target for Radiotherapy 
In contrast to normal cells that proliferate only in response to developmental or 
mitogenic signals, cancer cells undergo limitless replicative cycles (Hanahan & Weinberg, 
2000; Lapenna & Giordano, 2009). This does not mean that the cell cycle of cancer cells 
is basically different from normal cells; instead cancer cells proliferate because they are 
no longer subject to signals that govern normal cell proliferation and homeostasis 
(Deshpande et al., 2005; Hanahan & Weinberg, 2000). The cell cycle regulatory shunt in 
cancer cells mainly occurs via the acquisition of special capabilities such as growth signal 
autonomy, insensitivity to antigrowth signals and resistance to apoptosis (Deshpande et 
al., 2005; Hanahan & Weinberg, 2000). 
Similar to normal cells, cancer cells pass through the well-known phases of the cell 
cycle: Gap1 (G1), Synthetic phase (S phase), Gap2 (G2) and Mitosis (M phase) (Pines, 
1995; Sanchez & Dynlacht, 2005; Sherr, 1996). The progression of these different cell 
cycle phases is regulated by a family of protein kinases known as CDKs (Sanchez & 
Dynlacht, 2005; Sherr, 1996). CDKs, together with their regulatory proteins “Cyclins”, are 
considered as the molecular engine of the cell cycle machinery (Dickson & Schwartz, 
2009; Esposito et al., 2013; Halperin et al., 2008). 
Cell cycle kinetic plays a crucial role in the response of cells to ionising radiation. 
In general, proliferative cells are more susceptible to ionising radiation than non-
proliferative cells (Choy et al., 2008). The cytotoxic effect of radiotherapy depends on the 
position of the cell in the cell cycle. The cell cycle phase dependency of radiosensitivity of 
cells was first reported in HeLa cells by Terasima and Tolmach (Terasima & Tolmach, 
1963). In response to irradiation, cells in G2 and M phases of the cell cycle are the most 
radiosensitive, S phase cells are the most radioresistant and G1 cells show moderate 
radiosensitivity (Burki, 1980; Choy et al., 2008; Chuang & Liber, 1996; Dewey et al., 1970; 
Jostes et al., 1980; Leonhardt et al., 1997; Sinclair, 1968; Sinclair & Morton, 1963; 
Terasima & Tolmach, 1963; Watanabe & Horikawa, 1980). Therefore, the ability to 
manipulate the cell cycle regulation seems likely to have an important therapeutic impact 
on cancer treatment. For example, modulation of checkpoint response to DNA damage or 
elimination of the radioresistant S phase cell population may enhance the radiation 
response of cells to radiotherapy (Choy et al., 2008; Moretti et al., 2010). 
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2.2 Cell Cycle Checkpoints and DNA Damage Repair 
Several studies have reported that DNA is the main subcellular target for ionising 
radiation (Hallahan et al., 1993; Valentin, 2005). Among ionising radiation-induced DNA 
lesions are DNA base damage, single strand break (SSB) and double strand break (DSB) 
(Han & Yu, 2010). DNA base damages play a minor role in radiation mutagenesis and can 
be repaired via the base excision repair (BER) pathway (Han & Yu, 2010). Most of the 
SSBs are repaired through DNA ligation (Han & Yu, 2010; von Sonntag, 1987). On the 
contrary, DSBs are much more difficult to repair and persist as damaged DNA sites of 
about 15 to 20 nucleotides in size (Stewart, 2001; Ward, 1981). Inefficient repair of DSBs 
may lead to micronuclei formation, chromosome aberrations and deprivation of the 
proliferative integrity of the cell's genome (Baskar et al., 2012; Brock & Williams, 1985; 
Deschner & Gray, 1959; Difilippantonio et al., 2002; Goodhead, 1994; Hall, 1972; 
Helleday et al., 2007; Hoeijmakers, 2001; Lea, 1955; McBride & Withers, 2008; Vidal et 
al., 2001; Ward, 1988; Ward, 1995; Zhu et al., 2002). 
The initiation of each of the four successive cell cycle phases depends on the 
completion of the previous phase. Cell cycle checkpoints are the mechanisms that control 
this ordered dependency (Deckbar et al., 2011; Fleck & Nielsen, 2004; Lodish et al., 
2000a). In response to genotoxic stress, cells activate the DNA damage checkpoint 
pathways and arrest progression of the cells cycle (Su, 2006; Weitzman et al., 2013; 
Wohlbold & Fisher, 2009). The rationale behind the cell cycle arrest is to provide adequate 
time for DNA damage repair (Deckbar et al., 2011; Fleck & Nielsen, 2004; Weinert et al., 
1994; Weitzman et al., 2013; Yata & Esashi, 2009). After efficient DNA damage repair, 
cells are released from the cell cycle arrest and continue to divide (Soule et al., 2010). 
Loss or attenuation of cell cycle control may compromise the genome fidelity due to 
insufficient time to repair the DNA damage (Xing et al., 2007). 
There are two main DNA damage checkpoints: the G1/S checkpoint and the G2/M 
checkpoint (Bakkenist & Kastan, 2003; Latif et al., 2001; Sancar et al., 2004; Zhao et al., 
2002). The G1/S checkpoint occurs at the end of the G1 phase and functions to check the 
integrity of the genome before DNA replication (Figure  2.1) (d'Adda di Fagagna et al., 
2003). The G2/M checkpoint occurs at the end of the G2 phase and prevents cells with 
DNA lesions from entering mitosis (Deckbar et al., 2011; Fleck & Nielsen, 2004). 
The checkpoint responses are primarily induced via two protein kinases: Ataxia 
telangiectasia mutated protein (ATM) and ataxia telangiectasia and Rad3-related protein 
(ATR) (Abraham, 2001; Durocher & Jackson, 2001; Harper & Elledge, 2007). ATM is 
primary activated in response to DSBs. First, the trimeric MRN complex, which consists of 
Mre11 (Meiotic recombination 11 homologue), Rad50 (a structural maintenance of 
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chromosome protein) and NBS1 (Nijmegen breakage syndrome 1), recognises the sites of 
DSBs. ATM is then recruited to the DNA damage site by direct interaction with the MRN 
complex and is activated by phosphorylation at residue serine (S) 1981 (Bakkenist & 
Kastan, 2003; Berkovich et al., 2007). Active ATM phosphorylates the histone variant 2AX 
at S139 (γH2AX) around the site of the DNA damage leading to further accumulation of 
MRN complexes and amplification of the checkpoint signal (Bristow & Hill, 2008; Yata & 
Esashi, 2009). 
 
 
Figure  2.1. DNA damage checkpoints. G1/S and G2/M checkpoints are located at the end of 
the G1 and G2 phases, respectively. 
 
ATR, on the other hand, is mainly involved in the response to SSBs and stalled 
replication forks (Bartek & Lukas, 2007; Bohgaki et al., 2010; Jazayeri et al., 2006; Shiloh, 
2003). It is activated by the presence of single-strand DNA (ssDNA). Thereby, the 
ATR/ATR interacting protein (ATRIP) complex is recruited to the ssDNA region where it 
becomes fully activated (Jazayeri et al., 2006; Mordes et al., 2008). 
Activated ATM or ATR then phosphorylates and activates their downstream 
substrates such as checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2) and p53 
(Banin et al., 1998; Canman et al., 1998; Niida & Nakanishi, 2006). Via these downstream 
substrates, signalling from the components of the DNA damage response culminates in a 
checkpoint arrest (Latif et al., 2001). 
The activation of p53 plays a central role in G1 arrest in response to genotoxic 
stress. Upon DNA damage, p53 is phosphorylated by ATM or ATR at several 
phosphorylation sites on its transactivation domain (Banin et al., 1998; Chehab et al., 
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1999; Lim et al., 2000). The phosphorylation of p53 leads to the synthesis of CDK inhibitor 
1A (p21Cip1/Waf1/Sdi1) which binds to and inhibits the kinase activity of CDK2 and CDK4 
(Banin et al., 1998; Canman et al., 1998; Sancar et al., 2004; Tibbetts et al., 1999). This 
leads to p21-mediated G1 arrest (Figure  2.2) (Harper et al., 1993; Li et al., 1994). Several 
studies have demonstrated that the G1 checkpoint activation is a slow process. It takes up 
to 6 h to abolish the S phase entry (Deckbar et al., 2010; Gadbois & Lehnert, 1997; Linke 
et al., 1997). 
 
 
Figure  2.2. p53 activation mediates cell cycle arrest. The phosphorylation of p53 by ATM or 
ATR leads to the expression of p21 that inhibits the activity of CDKs (modified after Latif et al., 
2001). 
 
In the G2/M checkpoint, the activated CHK1 or CHK2 phosphorylates and inhibits 
the cell division cycle 25 (Cdc25) phosphatase activity (Deckbar et al., 2010; Zhao et al., 
2002). As the phosphatase activity of Cdc25 is required for removal of the inhibitory 
phosphates from CDKs, the inhibition of Cdc25 delays the activation of CDK1 and leads to 
G2 cell cycle arrest (Figure  2.3) (Mailand et al., 2000; Mailand et al., 2002). Another p53-
dependent pathway that induces a cell cycle G2/M arrest via transactivation of p21 has 
been described. However, the exact function of this pathway is not understood (Bruno et 
al., 2006; Chan et al., 2000; Lukas et al., 2004; Taylor & Stark, 2001). 
During the cell cycle arrest, there are two main mechanisms to repair DSBs in 
eukaryotic cells: non-homologous end-joining (NHEJ) and homologous recombination 
(HR) (Helleday et al., 2007; Sancar et al., 2004). NHEJ is an error-prone repair 
mechanism and usually results in deletions or insertions at the site of DNA damage. NHEJ 
is active during all cell cycle phases but the favoured DNA damage repair mechanism 
during the G1 and early S phases (Figure  2.4). On the other hand, HR is preferred during 
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late S and G2 phases and results in high-fidelity error-free repair (Couedel et al., 2004; 
Han & Yu, 2010; Mills et al., 2004; Rothkamm et al., 2003; Saintigny et al., 2001; Saleh-
Gohari & Helleday, 2004; Takata et al., 1998). 
 
 
Figure  2.3. ATM or ATR checkpoint signalling inhibits the activity of CDK/Cyclin 
complexes. In response to DNA damage, activated ATM or ATR phosphorylates and activates 
CHK1 and CHK2 that inhibit the Cdc25 phosphatase activity and prevent the activation of 
CDK/Cyclin complexes (modified after Yata & Esashi, 2009). 
 
 
 
Figure  2.4. NHEJ and HR are regulated differentially through the cell cycle. NHEJ is the 
dominant repair pathway in the G1 and early S phases but stays active throughout the cell 
cycle while HR is active only during late S and G2 (modified after Wohlbold & Fisher, 2009). 
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NHEJ ligates the two ends of a DSB without sequence homology (Han & Yu, 
2010). The first step in this process is the binding of Ku70/Ku80 heterodimer to the DNA 
ends (Fleck & Nielsen, 2004). The Ku heterodimer then recruits the catalytic subunit of 
DNA-PK (DNA-PKcs) to form the DNA-dependent protein kinase (DNA-PK) holoenzyme 
(Gottlieb & Jackson, 1993; Smith et al., 1999; Smith & Jackson, 1999; Yata & Esashi, 
2009). DNA-PKcs is activated by autophosphorylation and displays serine/threonine 
kinase activity (Han & Yu, 2010). Activated DNA-PKcs phosphorylates and activates 
additional repair proteins including the ARTEMIS nuclease. ARTEMIS or the MRN 
complex processes the DNA ends (Lans et al., 2012) that are then ligated by the 
XLF/XRCC4/DNA ligase IV complex (Figure  2.5) (Ahnesorg et al., 2006; Drouet et al., 
2005; Drouet et al., 2006; Fleck & Nielsen, 2004; Goodarzi et al., 2006; Yata & Esashi, 
2009). 
 
 
Figure  2.5. Schematic of the NHEJ pathway. Binding of Ku70/Ku80 heterodimer binds to 
DSB ends and recruits the catalytic subunit of DNA-PK (DNA-PKcs). The activated DNA-PKcs 
phosphorylates ARTEMIS which process the DSB ends. The MRN complex may also process 
the DSB ends. The XLF/XRCC4/DNA ligase IV (LigIV) complex joins the two broken DNA ends 
(modified after Lans et al., 2012).  
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HR repair, on the other hand, uses an undamaged sister chromatid or a 
homologous chromosome as a template for repair. The repair process starts with a 
nucleolytic resection of the DSB by the MRN complex in the 5’-3’ direction to generate 3’ 
ssDNA ends, which are bound by RPA. RAD52 binds to RPA and stimulates the binding 
of RAD51 to the 3’ ssDNA ends. Subsequently, RAD54 stimulates the RAD51-associated 
ssDNA to invade into the homologous duplex DNA. After repair synthesis and ligation, two 
Holliday junctions are formed and branch migration can occur. Finally, the holliday 
junctions are resolved (Figure  2.6) (Fleck & Nielsen, 2004; Han & Yu, 2010; West, 2003; 
Wyman & Kanaar, 2004). 
 
 
Figure  2.6. Schematic representation of the HR repair pathway. HR is initiated by DNA 
end-resection generating ssDNA ends. The generated ssDNA ends are bound by RPA, which 
is subsequently replaced by RAD51. RAD54 stimulates the invasion of the RAD51 flanked-
ssDNA ends to a homologous DNA template and promotes DNA synthesis and repair 
(modified after Fleck & Nielsen, 2004) 
 
2.3 Cyclin-Dependent Kinases 
CDKs are a group of serine/threonine protein kinases firstly discovered for their 
role in regulating the cell cycle (Malumbres & Barbacid, 2005; Nigg, 1995; Norbury & 
Nurse, 1992; Nurse, 1994; Orend et al., 2003; Pines, 1995; Schafer, 1998). Also, they are 
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implicated in many other cellular functions such as transcription regulation (transcriptional 
CDKs), mRNA processing and nerve cell differentiation (Bartkowiak et al., 2010; Blazek et 
al., 2011; Bres et al., 2008; Cruz & Tsai, 2004; Kohoutek & Blazek, 2012; Pirngruber et 
al., 2009; Romano & Giordano, 2008). The activity of CDKs is regulated either positively 
by Cyclins or negatively by CDK inhibitors. In addition, sequential phosphorylation and 
dephosphorylation events at certain threonine or tyrosine residues of CDKs control their 
activity (Obaya & Sedivy, 2002; Orend et al., 2003). Up to date, 13 CDK candidates 
(CDK1-CDK13) were indentified. At least four CDKs (CDK1, CDK2, CDK4 and CDK6) are 
directly involved in cell cycle regulation (cell cycle CDKs). 
Cell cycle CDKs act as on/off switches for the cell cycle of human cells and form, 
together with Cyclins, a panel of heterodimeric complexes that precisely regulate the 
progression of each cell cycle phase as well as the transition through the cell cycle 
phases (Figure  2.7) (Pavletich, 1999; Shapiro, 2006). 
 
 
Figure  2.7. The phases of the cell cycle (G1, S, G2 and M) and their regulatory 
CDK/Cyclin complexes. 
 
During the cell cycle, complexes of CDK4 or CDK6 with Cyclin D are activated in 
early G1 phase and phosphorylate the retinoblastoma protein (Rb) family members (Rb, 
p107 and p130) (Sherr, 1995; Sherr & Roberts, 2004). This leads to the release of the 
E2F transcription factor that initiates cell-cycle gene transcription and subsequently 
promotes cell cycle progression (Cobrinik, 2005; Dyson, 1998; Weinberg, 1995). Early 
E2F responsive genes include Cyclin E and Cyclin A (Boonstra & Post, 2004; Lundberg & 
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Weinberg, 1998; Malumbres & Barbacid, 2005; Sherr & Roberts, 1999). In the late G1 
phase, CDK2/Cyclin E activity completes the phosphorylation of Rb leading to G1/S phase 
transition and S phase initiation (Figure  2.8) (Boonstra & Post, 2004; Lundberg & 
Weinberg, 1998; Ohtsubo et al., 1995; Sherr & Roberts, 1999; Sherr & Roberts, 2004; 
Trimarchi & Lees, 2002).  
Later, CDK2/Cyclin A activity is required for the progression of the S phase and 
DNA duplication (Malumbres & Barbacid, 2005). At the end of the S phase, Cyclin A 
associates with CDK1. Both CDK2/Cyclin A and CDK1/Cyclin A complexes target several 
common substrates that are involved in the DNA replication (e.g. Cdc7) and the control of 
cell-cycle progression (e.g. Rb, p53 and BRCA2). During G2 phase, Cyclin A is degraded 
whereas Cyclin B is actively synthesised. The formation of CDK1/Cyclin B is believed to 
be essential for the initiation and progression of mitosis (Malumbres & Barbacid, 2005; 
Malumbres & Barbacid, 2009; Nigg, 2001; Riabowol et al., 1989). Finally, Cyclin B 
destruction is necessary for exit from mitosis (Murray, 1995; Sullivan & Morgan, 2007). 
 
 
Figure  2.8. The mechanism of the inhibitory phosphorylation of Rb. CDK4/Cyclin D and 
CDK2/Cyclin E complexes during the G1 phase release the E2F transcription factor. The E2F 
transcription factor starts transcription of a set of cell cycle genes leading to G1 phase 
progression and G1/S phase transition (modified after Daniel, 2002). 
 
CDK3/Cyclin C complexes are involved in re-entrance from G0 to G1 phase (Ren 
& Rollins, 2004) and CDK5 kinase activity regulates neuronal functions (Cruz & Tsai, 
2004). 
CDK7 together with Cyclin H and Mat1 form a trimeric multifunctional complex. 
This complex is able to regulate the cell cycle as CDK activating kinase (CAK) and the 
transcription via phosphorylating the carboxyl terminal domain (CTD) of RNA polymerase 
II (RNAP II) (Wallenfang & Seydoux, 2002). 
Background 
13 
 
CDK8-CDK13 (also known as transcriptional CDKs) are mainly involved in 
transcription regulation (Akoulitchev et al., 2000; Bartkowiak et al., 2010; Blazek et al., 
2011; Chen et al., 2006; Chen et al., 2007; Garriga & Grana, 2004; Hu et al., 2007; 
Kasten & Giordano, 2001; Kohoutek & Blazek, 2012). Recently, it was reported that CDK9 
functions to maintain the genomic integrity (Yu & Cortez, 2011; Yu et al., 2010). 
The activities of CDK/Cyclin complexes are regulated by two families of CDK 
inhibitors (INK4 family and Cip/Kip family). The INK4 family (p16INK4a, p15INK4b, p18INK4c, 
p19INK4d) specifically inhibits CDK4 and CDK6 activities while the Cip/Kip family 
(p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2) is able to inactivate all G1 CDK/Cyclin complexes and, to 
a lesser extent, CDK1/Cyclin B complexes (Aprelikova et al., 1995; Harper et al., 1995; 
Hengst & Reed, 1998; Lee et al., 1995; O'Connor, 1997; Polyak et al., 1994; Roussel, 
1999; Satyanarayana & Kaldis, 2009b; Soffar et al., 2013; Toyoshima & Hunter, 1994). 
2.4 Targeting of CDKs in Cancer Therapy 
Deregulation of the activity of cell cycle protein kinases is a hallmark of cancer 
(Esposito et al., 2013; Lapenna & Giordano, 2009; Malumbres & Barbacid, 2009; Rizzolio 
et al., 2010; Santamaria et al., 2007). Mutations resulting in overexpression or 
hyperactivation of CDKs in cancers have been reported in several studies (Easton et al., 
1998; Kim et al., 1999; Malumbres & Barbacid, 2009; McDonald & El-Deiry, 2000; Nevins, 
2001; Ortega et al., 2002; Tsihlias et al., 1999; Vermeulen et al., 2003; Wolfel et al., 1995; 
Yamamoto et al., 1998). Therefore, CDKs are regarded as promising targets for cancer 
therapy (Esposito et al., 2013; Graf et al., 2011; Rizzolio et al., 2010). 
The intensive research for small molecule pharmacological inhibitors targeting 
CDKs resulted in the identification of various candidates that are able to inhibit CDK 
activity and cease proliferation (Canavese et al., 2012; Diaz-Padilla et al., 2009; Lapenna 
& Giordano, 2009; Malumbres et al., 2008). The major CDK targets of these inhibitors are 
CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 (Graf et al., 2011). First-generation CDK 
pharmacological inhibitors (e.g. Flavopiridol and R-Roscovitine) are now in late-stage 
clinical trials (Canavese et al., 2012; Colevas et al., 2002; Kelland, 2000). However, these 
pharmacological inhibitors have shown only modest activity (Byrd et al., 2007; Malumbres 
et al., 2008). A second generation of CDK pharmacological inhibitors (e.g. ZK 304709) are 
now under investigation in advanced preclinical or clinical studies (Malumbres et al., 2008; 
Siemeister et al., 2006). Nevertheless, none of these molecules has already been 
approved as a drug for cancer therapy (Galons et al., 2010; Graf et al., 2011). 
Despite their critical role on several cellular functions and the intensive 
investigation of these proteins as potential cancer targets, studies evaluating the role of 
CDKs as molecular targets to enhance cancer response to ionising radiation are rare. 
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In this work, we investigated two candidates of the CDK family, CDK2 and CDK9, 
as potential molecular targets to enhance the cancer cell response to ionising radiation. 
2.4.1 CDK2 
Structurally, CDK2 exhibits a large protein kinase domain which contains three 
important phosphorylation sites (Endicott et al., 1999; Johnson & Lewis, 2001). The two 
deactivating phosphorylation sites are threonine (T) 14 and tyrosine (Y) 15 and the 
activating phosphorylation site is T160 (Figure  2.9A). X-ray crystallography revealed that 
CDK2 is composed of a small N-terminal lobe and a large C-terminal lobe (Figure  2.9B) 
(De Bondt et al., 1993). The amino (N)-terminal lobe comprises of a highly conserved 
beta-sheet (Baumli et al., 2008), while the carboxyl (C)-terminal lobe is composed of six 
alpha-helices and one beta-sheet. This two-lobed structure forms an adenosine 
triphosphate (ATP)-binding cleft constituting the active site (Hanks & Hunter, 1995; Hu et 
al., 1994; Ubersax & Ferrell, 2007). Activation of CDK2 requires binding of a regulatory 
cyclin unit such as Cyclin E or Cyclin A, phosphorylation of T160 by a CAK and 
dephosphorylation on T14/Y15 by Cdc25 for complete kinase activation (Bartova et al., 
2004; Lunn et al., 2010). 
CDK2 as a target for cancer therapy attracted increasing attention as it contributes 
to vital cell cycle regulatory pathways such as G1 phase progression, cell cycle transitions 
(G1/S as well as G2/M phase transitions) and G2/M checkpoint activation (Aleem et al., 
2004; Kaldis & Aleem, 2005; Sherr & Roberts, 2004). Furthermore, CDK2 targets a set of 
substrates that regulate G1/S checkpoint and DNA damage repair response (Esashi et al., 
2005; Muller-Tidow et al., 2004; Myers et al., 2007; Neganova et al., 2011; Ruffner et al., 
1999; Satyanarayana & Kaldis, 2009b). Several studies reported that CDK2/Cyclin A 
complex regulates substrates that are involved in NHEJ (e.g. Ku70) (Lee & Desiderio, 
1999; Lin & Desiderio, 1994; Muller-Tidow et al., 2004). Moreover, DNA Polymerase λ, a 
protein involved in regulating NHEJ as well as BER, is also a substrate of CDK2 (Frouin et 
al., 2005; Wimmer et al., 2008; Wohlbold & Fisher, 2009). CDK2 also regulates ATRIP 
phosphorylation on S224 and modulates the ability of ATR/ATRIP complex to promote cell 
cycle arrest in response to DNA damage (Myers et al., 2007). 
In this work, the investigation of CDK2 as a target to modulate the cellular radiation 
response of HNSCC is based on its role cell cycling and DNA damage repair (Esashi et 
al., 2005; Muller-Tidow et al., 2004; Myers et al., 2007; Neganova et al., 2011; Ruffner et 
al., 1999; Satyanarayana et al., 2008; Satyanarayana & Kaldis, 2009b) as well as on 
unpublished data generated by Prof. Cordes and Prof. Aleem (Alexandria University, 
Egypt) show that CDK2-/- MEFs are more radiosensitive than WT MEFs. 
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Figure  2.9. Structure of human CDK2. (A) Schematic of CDK2 showing the protein kinase 
domain (red), the inhibitory phosphorylation sites T14 and Y15 and the activating 
phosphorylation site T160. (B) Crystal structure of human CDK2 (http://www.phosphosite.org 
(CDK2-human-1AQ1)). CDK2 is composed of a small N-terminal lobe (right) and a large C-
terminal lobe (left). Protein substrates bind to the active CDK2/Cyclin complex in the wide cleft 
between the small and large lobes (De Bondt et al., 1993). 
 
2.4.2 CDK9 
The structure of CDK9 is similar to CDK2 (Baumli et al., 2008). It contains a 
conserved protein kinase domain with an activating phosphorylation site (T186) (Figure 
 2.10A) (Baumli et al., 2008). CDK9 has a C-terminal tail with a largely non-conserved 
sequence (Baumli et al., 2012). This C-terminal tail is necessary for the nuclear import of 
the CDK9/Cyclin complex (Napolitano et al., 2003). CDK9 is composed of two lobes 
(Figure  2.10B). The N-terminal lobe is mainly comprised of beta-sheet and the C-terminal 
lobe is mainly consisted of alpha-helices (Baumli et al., 2008). 
CDK9 is activated by forming heterodimeric complexes with either Cyclin T or 
Cyclin K families (Garriga et al., 2003; Peng et al., 1998; Yu & Cortez, 2011; Zhu et al., 
1997). The activity of CDK9 is inhibited by both 7SK and HEXIM1 proteins (Michels et al., 
2004). 
CDK9 together with Cyclin T or Cyclin K form a complex known as positive 
transcription elongation factor b (pTEFb). This complex promotes transcription elongation 
by phosphorylating the CTD of the large subunit of RNAPII (Rpb1-CTD) on the S2 residue 
(Yu & Cortez, 2011). CDK9 also phosphorylates Rpb1-CTD on S5 (Ramanathan et al., 
2001; Zhou et al., 2000). pTEFb modulates other cellular functions such as co-
transcriptional histone modification, mRNA processing and mRNA export (Bres et al., 
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2008; Pirngruber et al., 2009; Romano & Giordano, 2008). A recent study showed that 
CDK9 together with Cyclin K but not cyclin T are involved in maintaining the genome 
integrity after replication stress (Yu et al., 2010). 
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Figure  2.10. Structure of human CDK9. (A) Schematic of CDK9 showing the protein kinase 
domain (green) and the activating phosphorylation site T186. (B) Crystallographic structure of 
human CDK9 (http://www.phosphosite.org (CDK9-human-1PF6)). 
 
Recently, CDK9 was reported to impact the cell cycle recovery after a transient 
pulse of Hydroxyurea or Aphidicolin and stimulates γH2AX phosphorylation in the absence 
of exogenous damage (Liu & Herrmann, 2005; Yu et al., 2010). In addition, co-
immunoprecipitation studies showed that the CDK9/Cyclin K complex interacts with ATR, 
ATRIP and other DNA repair and checkpoint signalling proteins suggesting that 
CDK9/Cyclin K plays a role in maintaining genome integrity (Yu et al., 2010). 
Based on its recently described role in DNA damage repair response, we 
investigated CDK9 as a target to improve cancer cell response to radiotherapy. 
 
Aim of Work 
17 
 
 
3 Aim of Work 
The radiosensitivity of tumour cells depends mainly on their capacity to maintain 
genomic integrity. This requires efficient repair of radiation-induced DNA DSBs (Dikomey 
& Brammer, 2000; Hanahan & Weinberg, 2000; Jeggo & Lobrich, 2006a; Karnoub & 
Weinberg, 2008), a process governed by the cell cycle. Particularly, the action of 
integrating the molecular mechanisms of radiation-induced damage and cell cycling is still 
not well understood (Dikomey & Brammer, 2000; Iliakis et al., 2003; Jeggo & Lobrich, 
2006b). 
The crucial role of CDKs in cell cycling and DNA damage repair and the frequent 
aberrations of their activities in cancer encouraged an intensive screening for small-
molecule CDK pharmacological inhibitors that block the CDK activity (Canavese et al., 
2012; Diaz-Padilla et al., 2009; Malumbres et al., 2008). Despite the intensive research 
regarding CDKs as target for cancer therapy, studies evaluating their role in response of 
cancer cells to irradiation are rare. 
Therefore, the aim of this work is to identify the molecular role of CDK2 and CDK9 
in cellular response of human HNSCC cancer cells to ionising radiation. To achieve this 
goal, we analysed several parameters such as clonogenic cell survival, DNA repair, cell 
cycle progression, apoptosis induction and expression and phosphorylation of various cell 
cycle and DNA repair proteins. Furthermore, we elucidated the relationship between the 
cell cycle/DNA repair regulatory events and tumour cell survival which might contribute to 
the optimisation of cancer treatment. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Cell Lines 
WT and CDK2-/- MEFs were generated as described in (Berthet et al., 2003) and 
were kindly provided by Prof. E. Aleem, Alexandria University, Egypt. Human SAS, FaDu, 
HSC4, Cal33, UTSCC5 and UTSCC8 HNSCC cell lines were a kind gift of Prof. R. 
Grenman, Turku University Central Hospital, Finland and Prof. M. Baumann, Dresden 
University of Technology, Germany. 
SAS-CDK9-EGFP and SAS-EGFP cells were generated as described in section 
 4.4. 
4.1.2 Bacteria 
XL1-Blue competent Escherichia coli (Agilent Technologies, Inc., California, United 
States) was used as host organism. The genotype of these cells is: recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacIqZ∆M15 Tn10(Tetr)]. 
4.1.3 Plasmid 
In order to amplify the CDK9 gene, the full coding DNA sequence of human WT 
CDK9 was cloned between the cytomegalovirus (CMV) promoter region and the 
enhanced green fluorescence protein (EGFP) encoding region of the pEGFP-N1 plasmid 
(Invitrogen, Karlsruhe, Germany) (Section  4.4). 
4.1.4 Equipments 
Device Model Manufacturer 
Autoclave V-65 Systec, Wettenberg, Germany 
Bacterial incubator  Memmert, Schwabach, Germany 
Barometer  Conrad Electronics, Hirschau, Germany 
Bio Imaging System Gene Genius Syngene, Cambridge, Great Britain 
Centrifuge 5804R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Centrifuge Minispin® Eppendorf, Hamburg, Germany 
CO2 incubator Heracell Heraeus Holding GmbH, Hanau, Germany 
Cooled vertical 
electrophoresis Unit 
SE 600 Hoefer, San Francisco, USA 
Counting chamber Neubauer bright 
line 
Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany 
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Device Model Manufacturer 
Dosimeter PTW Unidos PTW, Freiburg, Germany 
Flow cytometer CyFlow Partec GmbH, Münster, Germany 
Fluorescence microscope Axioskop 2 plus Carl Zeiss, Jena, Germany 
Freezer -20 ºC KX1011 Liebherr, Ochsenhausen, Germany 
Freezer -80 ºC  Heraeus Holding GmbH, Hanau, Germany 
Ice machine AT910 Scotsman, London, Great Britain 
Incubation shaker CERTOMAT®IS B. Braun Melsungen AG, Melsungen, 
Germany 
Incubator for cell culture 
solutions 
 Heraeus Holding GmbH, Hanau, Germany 
Inverted microscope Axiovert 25 Carl Zeiss, Jena, Germany 
Inverted fluorescence 
microscope 
Axiovert 40 CFL Carl Zeiss, Jena, Germany 
Inverted fluorescence 
microscope 
Axio Observer Z1 Carl Zeiss, Jena, Germany 
Laminar flow cabinet Clean Air Heraeus Holding GmbH, Hanau, Germany 
Laser scanning microscope 
(LSM) 
Axiovert 200M, 
LSM 510 Meta 
Carl Zeiss, Jena, Germany 
Magnetic stirrer with heater MR 3001 Heidolph, Schwabach, Germany 
Manual piece counter T 120 IVO, Villingen-Schwenningen, Germany 
Microcentrifuge 5415R Eppendorf, Hamburg, Germany 
Microwave  Sharp Electronics (Europe) GmbH, 
Hamburg, Germany 
Mini-vertical electrophoresis 
unit 
SE 250 Hoefer, San Francisco, USA 
Multidimensional platform 
shaker 
Polymax 1040 Heidolph, Schwabach, Germany 
Nanodrop® 
Spektrophotometer 
ND-1000 PeqLab Biotechnologie GmbH, Erlangen, 
Germany 
Orbital shaker KS 260 basic IKA, Staufen, Germany 
Plastic sealer machine Dual Electronic Jencons-PLS, London, Great Britain 
pH meter ph Level 1 inoLab, Weilheim, Germany 
Photo scanner Perfection 4490 
PHOTO 
Epson, Meerbusch, Germany 
Power supply EPS601 Amersham, Freiburg, Germany 
Precision balance LE244S-0CE Sartorius, Göttingen, Germany 
Refrigerator  Liebherr, Ochsenhausen, Germany 
Roller mixer SRT1 Stuart Scientific Ltd., Bath, Great Britain 
Scale BL 1500 S Sartorius, Göttingen, Germany 
Semi-dry transfer unit TE77 Amersham, Freiburg, Germany 
Stereo-microscope with light 
source 
Stemi-2000 Carl Zeiss, Jena, Germany 
Tecan microplate reader Genios Pro Tecan, Crailsheim, Germany 
Thermocycler Mastercycler 
epgradient 
Eppendorf, Hamburg, Germany 
Thermomixer Comfort 1.5 ml Eppendorf, Hamburg, Germany 
Vacuum pump Vacusafe comfort VacuSafe IBS Integra Bioscience, Chur, 
Switzerland 
Vortex mixer Reax control VWR, Darmstadt, Germany 
Washer disinfector Compact 
disinfector G7783 
CD 
Miele & Cie. KG, Gütersloh, Germany 
Water bath SW22 Julabo Labortechnik GmbH, Seelbach, 
Germany 
Water purification system Milli-Q® Millipore, Schwalbach/Ts., Germany 
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Device Model Manufacturer 
X-ray irradiator Xylon Y.TU 320 Xylon, Zurich, Switzerland 
 
4.1.5 Computer Software 
Software Version Developer 
AxioVision Release 
4.8.2 
Carl Zeiss, Jena, Germany 
FloMax 2.70 Quantum Analysis GmbH, Münster, Germany 
Gap4  STADEN Software Package (Staden et al., 2000) 
GraphPad Prism 4.03 GraphPad Software Inc., San Diego, USA 
ImageJ 1.47g Wayne Rasband, National Institutes of Health, USA 
Magellan 5.0 Tecan, Crailsheim, Germany 
Microsoft Excel 2003 Microsoft Corp., Redmond, WA, USA 
ND-1000 3.3.0 NanoDrop Technologies, Inc. Wilmington, DE, USA 
Zeiss LSM image browser 3,5,0,376 Carl Zeiss GmbH, Jena, Germany 
 
4.1.6 Other Materials 
Name Manufacturer 
Caliper OBI, Wermelskirchen, Germany 
Cell scraper (18, 40 cm) BD, Heidelberg, Germany 
Conical centrifuge tube (15, 50 ml) BD, Heidelberg, Germany 
Cover glass Menzel GmbH & Co. KG, Braunschweig, Germany 
Cover slips (round) Glaswarenfabrik Karl Hecht KG, Sondheim, 
Germany 
Cryotubes Biochrom, Berlin, Germany 
Eppendorf® Safe-Lock microcentrifuge 
tube (0.5, 1.5, 2 ml) 
Eppendorf, Hamburg, Germany 
Filter tips, sterile (10, 100, 200, 1000 µl) Fisher Scientific GmbH, Schwerte, Germany 
Freezing box Nalgene, Rochester, NY, USA 
Glass Pasteur pipette Brand GmbH u. Co. KG, Wertheim, Germany 
Hamilton 700 Series Microliter™ syringe 
(50, 100 µl) 
Hamilton Bonaduz AG, Bonaduz, GR, Switzerland 
HyperFilm® ECL™ Amersham, Freiburg, Germany 
Ice tub Roth, Karlsruhe, Germany 
Insulin syringe, 0.3 mm x 12 mm Braun, Melsungen, Germany 
Laboratory bottles Schott AG, Mainz, Germany 
Metal plates Eigenbau, UKD, Dresden, Germany 
Microscopic slide Roth, Karlsruhe, Germany 
Protran® nitrocellulose membrane, 0.2 
µm 
Whatman, Dassel, Germany 
Non-tissue culture plate (96-well) Corning Life Science, Wiesbaden, Germany 
Pipette (1, 5, 10, 25 ml) BD, Heidelberg, Germany 
Pipette controller, accu-jet® pro Brand, Herrenberg, Germany 
Thermometer Conrad Electronics, Hirschau, Germany 
Tissue culture dish (60, 100 mm) Greiner Bio-one GmbH, Frickenhausen, Germany 
Tissue culture flask (T25, T75, T175) BD, Heidelberg, Germany 
Tissue culture plate (6-, 12-, 24-, 48-, 96-
well) 
Roth, Karlsruhe, Germany 
Whatman-filter paper Bender-Hobein, Zurich, Switzerland 
X-ray cassette Amersham, Freiburg, Germany 
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4.1.7 Small interfering RNAs (siRNAs) 
Name Sequence  siRNA ID Company 
Sense: 5’-GGAGCUUAACCAUCCUAAUtt-3‘ hCDK2 
siRNA#1 Antisense: 3’-AUUAGGAUGGUUAAGCUCCtt-5‘ 
#42820 Applied Biosystems 
(Darmstadt, Germany) 
Sense: 5’-GGAAGUUUCAGUAUUAGAUtt-3‘ hCDK2 
siRNA#2 Antisense: 3’-AUCUAAUACUGAAACUUCCtt-5‘ 
#1409 Applied Biosystems 
(Darmstadt, Germany) 
Sense: 5’-GGAGAAUUUUACUGUGUUUtt-3‘ hCDK9 
siRNA#1 Antisense: 3’-AAACACAGUAAAAUUCUCCtg-5‘ 
#104 Applied Biosystems 
(Darmstadt, Germany) 
Sense: 5’-GGUGCUGAUGGAAAACGAGtt-3‘ hCDK9 
siRNA#2 Antisense: 3’-CUCGUUUUCCAUCAGCACCtt-5‘ 
#103 Applied Biosystems 
(Darmstadt, Germany) 
Sense: 5’-GCAGCUAUAUGAAUGUUGUtt-3‘ Control 
siRNA Antisense: 3’-CGUACGCGGAAUACUUCGAtt-5‘ 
 Applied Biosystems 
(Darmstadt, Germany) 
 
4.1.8 Primers 
Name Sequence  Melting 
temperature 
(Tm) 
Company 
hCDK9-
NheI 
forward 
5’- cta GCTAGC gccgcc ATGGCAAAGCAGTACGACTCGG-3’ 68°C Eurofins 
MWG 
Operon 
hCDK9-
BamHI 
reverse 
5’- cg GGATCC cg GAAGACGCGCTCAAACTCCG -3’ 64°C Eurofins 
MWG 
Operon 
 
4.1.9 Enzymes 
Polymerase chain reaction (PCR) was performed using a HotStarTaq® Plus 
Polymerase, 10x Buffer, MgCl2, dNTPs (Qiagen, Hilden, Germany) mixture. DNA 
restriction digest was performed using NheI, BamHI and ApaLI. T4 ligase (Invitrogen, 
Karlsruhe, Germany) was used to ligate digested DNA fragments. 
4.1.10 Protein and DNA Ladders 
The Benchmark™ protein ladder (Invitrogen, Karlsruhe, Germany) served as a 
molecular weight standard for sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). For agarose gel electrophoresis, the Range mix DNA 
ladder (0.08-10.0 kb) (PEQLAB Biotechnologie, Erlangen, Germany) was used for 
evaluation of DNA fragment size. 
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4.1.11 Kits 
Name Purpose Company 
Pierce® BCA Protein 
Assay Kit 
Protein concentration 
measurement 
Thermo Fisher Scientific 
p/a Perbio Science Deutschland 
Zweigniederlassung der Thermo Fisher 
Scientific Germany BV & Co KG, Bonn, 
Germany 
NucleoSpin® Plasmid Plasmid Miniprep Macherey-Nagel, Düren, Germany 
NucleoSpin® Extract II PCR product purification Macherey-Nagel, Düren, Germany 
Nucleobond® AX Plasmid Midiprep Macherey-Nagel, Düren, Germany 
Super Signal West 
Dura Extended 
Western blot horse reddish 
peroxidase signal detection 
Thermo Fisher Scientific 
p/a Perbio Science Deutschland 
Zweigniederlassung der Thermo Fisher 
Scientific Germany BV & Co KG, Bonn, 
Germany 
 
4.1.12 Primary Antibodies 
Name [Clone] Source, 
Isotype 
Application Dilution Supplier 
β-actin [AC-15] Mouse IgG1, 
Monoclonal 
Western Blotting 1:10,000 Sigma-Aldrich, 
Taufkirchen, Germany 
ATM [D2E2] Rabbit IgG, 
Monoclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
5-Bromo-2´-
deoxyuridine 
(BrdU) [B44] 
Mouse IgG1, 
Monoclonal 
Flow Cytometry 1:10 BD, Heidelberg, 
Germany 
CDK2 [78B2] Rabbit IgG, 
Monoclonal 
Western Blotting 1:500 Cell Signaling, 
Frankfurt a.M., 
Germany 
CDK9 [C12F7] Rabbit IgG, 
Monoclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
CHK2 Rabbit, 
Polyclonal 
Western Blotting 1:500 Cell Signaling, 
Frankfurt a.M., 
Germany 
Cyclin A Rabbit IgG, 
Polyclonal 
Western Blotting 1:1000 Santa Cruz, 
Heidelberg, Germany 
Cyclin D1 [D1-72-
13G] 
Mouse IgG1, 
Monoclonal 
Western Blotting 1:500 Zymed Laboratories 
Inc., California, USA 
Cyclin E [HE12] Mouse IgG1, 
Monoclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
DNA-PK Rabbit, 
Polyclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
GFP Rabbit, 
Polyclonal 
Western Blotting 1:2000 Abcam, Cambridge, 
UK 
ORC1 [7A7] Rabbit IgG1, 
Monoclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
p27(Kip1) 
[57/Kip1/p27] 
Mouse IgG1, 
Monoclonal 
Western Blotting 1:1000 BD, Heidelberg, 
Germany 
     
Materials and Methods 
23 
 
     
Name [Clone] Source, 
Isotype 
Application Dilution Supplier 
p53 binding protein 
1 (53BP1) 
Rabbit, 
Polyclonal 
Immunofluorescence 1:2000 Novus Biologicals, 
Littelton, USA 
P95/NBS1 Rabbit 
Polyclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
phospho-
ATM(S1981) 
[10H11.E12] 
Mouse IgG1, 
Monoclonal 
Western Blotting 1:500 Cell Signaling, 
Frankfurt a.M., 
Germany 
phospho-
CHK2(T86) 
Rabbit, 
Polyclonal 
Western Blotting 1:500 Cell Signaling, 
Frankfurt a.M., 
Germany 
phospho-Histone 
2AX(S139) (γH2AX) 
[JBW301] 
Mouse IgG1, 
Monoclonal 
Immunofluorescence 1:1000 Millipore, Darmstadt, 
Germany 
phospho-Rb(S795) Rabbit, 
Polyclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
phospho-Rpb1-
CTD(S2/5) 
Rabbit, 
Polyclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
PCNA [F-2] Mouse 
IgG2a, 
Monoclonal 
Western Blotting 1:500 Santa Cruz, 
Heidelberg, Germany 
RAD50 Rabbit, 
Polyclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
Rb Rabbit, 
Polyclonal 
Western Blotting 1:1000 Santa Cruz, 
Heidelberg, Germany 
RPA70 Rabbit 
Polyclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
Rpb1-CTD [4H8] Mouse IgG1, 
Monoclonal 
Western Blotting 1:1000 Cell Signaling, 
Frankfurt a.M., 
Germany 
 
4.1.13 Secondary Antibodies 
Antibody name Application Dilution Company 
Alexa488 anti-rabbit Immunofluorescence 1:2000 Invitrogen, Karlsruhe, 
Germany 
Alexa594 anti-mouse Immunofluorescence 1:2000 Invitrogen, Karlsruhe, 
Germany 
Anti-mouse IgG FITC Flow Cytometry 1:100 Sigma-Aldrich, 
Taufkirchen, Germany 
Anti-rat-peroxidase Western Blotting 1:5000 Sigma-Aldrich, 
Taufkirchen, Germany 
Goat anti-mouse (HRP-
conjugated) 
Western Blotting 1:5000, 
1:10,000 
Amersham, Freiburg, 
Germany 
Goat anti-rabbit (HRP-
conjugated) 
Western Blotting 1:5000 Amersham, Freiburg, 
Germany 
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4.1.14 Reagents 
4.1.14.1 Cell Culture and Transfection 
Name Composition Storage Company 
1 g Agarose, Typ I-A in 100 ml 
ddH2O 
Sigma, Taufkirchen, 
Germany 
Agarose (1%) 
100 ml ddH2O 
RT 
 
500 ml DMEM PAA, Cölbe, Germany 
50 ml FBS PAA, Cölbe, Germany 
Complete medium 
5.5 ml NEAA 
4°C 
PAA, Cölbe, Germany 
500 ml complete medium  Complete medium (1.5 
mg/ml G418) 7.5 ml G418 (100 mg/ml) 
4°C 
 
0.5 g Coomassie G250 J.T. Baker, Deventer, 
Netherland 
75 ml Glacial acetic acid Merck, Darmstadt, 
Germany 
200 ml Methanol Merck, Darmstadt, 
Germany 
Coomassie stain 
725 ddH2O 
RT 
 
Dulbecco's modified 
Eagle's medium (DMEM)  
Glucose (4.5 g/l) with stable 
Glutamine 
4°C PAA, Cölbe, Germany 
800 ml 99% Ethanol Berkel, Berlin, 
Germany 
Ethanol (80%) 
200 ml ddH2O 
RT 
 
Fetal bovine serum (FBS)  -20°C PAA, Cölbe, Germany 
8.5 ml Complete medium  
1 ml FBS PAA, Cölbe, Germany 
Freezing medium 
0.5 ml DMSO 
-20°C 
AppliChem GmbH, 
Darmstadt, Germany 
25 g G418 Sulphate PAA, Cölbe, Germany Geneticin® (G418) (100 
mg/ml) ddH2O to a final volume of    
250 ml 
-20°C 
 
Matrigel™ basement 
membrane matrix high 
concentration (lrECM) 
(20 mg/ml) 
 -20°C BD, Heidelberg, 
Germany 
5 ml Matrigel™ basement 
membrane matrix high 
concentration 
Matrigel™ basement 
membrane matrix in 
DMEM (10 mg/ml) 
5 ml DMEM 
4°C  
1 ml Matrigel™ basement 
membrane matrix (10 mg/ml) 
Matrigel™ basement 
membrane matrix in 
complete medium (5 
mg/ml) 
1 ml complete medium 
4°C  
MEM non-essential 
amino acids (NEAA) 10 
mM (100x) 
 4°C PAA, Cölbe, Germany 
Oligofectamine® 
transfection reagent 
 4°C Invitrogen, Karlsruhe, 
Germany 
8 ml Opti-MEM® Invitrogen, Karlsruhe, 
Germany 
Opti-MEM® (20% FBS) 
2 ml FBS 
RT 
PAA, Cölbe, Germany 
Opti-MEM® I reduced 
serum medium, 
GlutaMAX™ 
 4°C Invitrogen, Karlsruhe, 
Germany 
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Name Composition Storage Company 
Phosphate-buffered 
saline (PBS) (1x) 
 RT PAA, Cölbe, Germany 
Trypsin-EDTA (1x)  -20°C PAA, Cölbe, Germany 
 Note: Used FBS was heated to 56°C for 30 min in a water bath to destroy heat-
labile complement proteins. 
 
4.1.14.2 Flow Cytometry 
Name Composition Storage Company 
15.35 mg BrdU Serva, Heidelberg, 
Germany 
BrdU (1 mM) 
in 50 ml PBS, filtered (sterile) 
-20°C 
 
1 g BSA Sigma, Taufkirchen, 
Germany 
BSA in 1xPBS (PBSA) 
(1%) 
1x PBS to a final volume of  
100 ml 
4°C 
 
80 ml 99% Ethanol Berkel, Berlin, 
Germany 
Ethanol (80%) 
20 ml ddH2O 
-20°C 
 
16.6 ml 37% HCl Merck, Darmstadt, 
Germany 
Hydrochloric acid (HCl) 
(2N) 
ddH2O to a final volume of    
100 ml 
RT 
 
50 mg Pepsin Merck, Darmstadt, 
Germany 
Pepsin solution (0.05%) 
(Freshly prepared) 
100 ml ddH2O 
4°C 
 
2.5 mg PI Serva, Heidelberg, 
Germany 
Propidium Iodide (PI) 
solution (25 µg/ml) 
100 ml 1x PBS 
4°C 
(Dark) 
 
10 mg RNase Sigma, Taufkirchen, 
Germany 
Ribonuclease A (RNase ) 
solution (0.01%) 
100 ml 1x PBS 
4°C 
 
 
4.1.14.3 SDS-PAGE and Western Blotting 
Name Composition Storage Company 
Acrylamide-bisacrylamide 
solution (30%) 
 4°C Serva, Heidelberg, Germany 
10 g APS AppliChem GmbH, Darmstadt, 
Germany 
Ammonium persulphate 
(APS) solution (10%) 
ddH2O to a final 
volume of 100 ml 
-20°C 
 
0.5 g BSA Sigma, Taufkirchen, Germany BSA in PBST (5%) 
PBST to a final 
volume of 10 ml 
4°C 
 
One tablet Roche Diagnostics GmbH, 
Mannheim, Germany 
Complete™ 
protease inhibitor (25x) 
in 2 ml ddH2O 
-20°C 
 
7.306 g EDTA Roth, Karlsruhe, Germany 
ddH2O to a final 
volume of 50 ml 
 
EDTA (500 mM) (pH 8.0) 
pH adjusted to 8.0 
RT 
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Name Composition Storage Company 
250 ml GBX 
Developer Kodak 
Kodack, Stuttgart, Germany Film developer 
(GBX Developer Kodak) 
750 ml ddH2O 
RT, Dark 
 
250 ml GBX Fixer 
Kodak 
Kodack, Stuttgart, Germany Film fixer 
(GBX Fixer Kodak) 
750 ml ddH2O 
RT 
 
25 ml Gycerol Roth, Karlsruhe, Germany Gycerol (50%) 
25 ml ddH2O 
RT 
 
Isopropanol (Propan-2-ol)  RT Merck, Darmstadt, Germany 
5 g Milk powder AppliChem GmbH, Darmstadt, 
Germany 
Milk buffer (5%) 
PBS (1x) to a final 
volume of 100 ml 
4°C 
 
29 g Glycine Roth, Karlsruhe, Germany 
58 g Tris Roth, Karlsruhe, Germany 
Maniatis-SDS blotting buffer 
(10x) 
ddH2O to a final 
volume of 1 l 
RT 
 
100 ml Maniatis-
SDS Blotting buffer 
(10x) 
 
200 ml Methanol J.T. Baker, Deventer, 
Netherland 
Maniatis-SDS blotting buffer 
(1x) 
700 ml ddH2O 
RT 
 
951 µl RIPA stock 
solution 
 
40 µl Complete™ 
Protease Inhibitor 
(25x) 
 
5 µl Na3VO4      
(200 mM) 
 
Modified RIPA lysis buffer 
4 µl NaF (500 mM) 
4°C 
 
3.678 g Na3VO4 Sigma, Taufkirchen, Germany Na3VO4 (200 mM) 
ddH2O to a final 
volume of 100 ml  
-20°C 
 
14.61 g NaCl Merck, Darmstadt, Germany NaCl (5 M) 
ddH2O to a final 
volume of 50 ml  
RT 
 
2.1 g NaF Sigma, Taufkirchen, Germany NaF (500 mM) 
ddH2O to a final 
volume of 100 ml, 
activated at          
pH 10.0 
-20°C 
 
100 ml PBS (20x)  PBS (1x) 
1900 ml ddH2O 
RT 
 
0.5 ml Tween 20 Serva, Heidelberg, Germany PBS(1x)/0.05% Tween 20 
(PBST) 1 l PBS (1x) 
RT 
 
160 g NaCl  Merck, Darmstadt, Germany 
4 g KCl  Merck, Darmstadt, Germany 
36 g Na2HPO4 Merck, Darmstadt, Germany 
4.8 g KH2PO4 Merck, Darmstadt, Germany 
ddH2O to a final 
volume of 1 l 
 
PBS stock solution (20x) 
(pH 7.4) 
pH adjusted at 7.4 
RT 
 
Ponceau S  RT Sigma, Taufkirchen, Germany 
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Name Composition Storage Company 
200 µl Reduced 
electrophoresis 
loading buffer (6x) 
 Reduced electrophoresis 
loading buffer (1x) 
1 ml ddH2O 
-20°C 
 
5 ml Glycerol (50%)  
925 mg DTT AppliChem GmbH, Darmstadt, 
Germany 
1.03 g SDS Roth, Karlsruhe, Germany 
3.5 ml Tris-HCl     
(1 M) pH 6.8 
 
1.2 mg 
Bromophenol blue 
AppliChem GmbH, Darmstadt, 
Germany 
Reduced electrophoresis 
loading buffer (6x) 
ddH2O to a final 
volume of 10 ml 
-20°C 
 
12.5 ml Tris-HCl   
(1 M) (pH 7.4) 
Roth, Karlsruhe, Germany 
2.5 ml NP-40 Fluka, München, Germany 
6.25 ml Sodium 
deoxycholate 
(10%) 
 
7.5 ml NaCl (5 M)  
0.5 ml EDTA (0.5 
M) (pH 8.0) 
 
RIPA stock solution 
ddH2O to a final 
volume of 250 ml 
4°C 
 
5 g SDS Roth, Karlsruhe, Germany SDS (10%) 
ddH2O to a final 
volume of 50 ml 
RT 
 
30.3 g Tris Roth, Karlsruhe, Germany 
144.1 g Glycine Roth, Karlsruhe, Germany 
10 g SDS Roth, Karlsruhe, Germany 
SDS-PAGE running buffer 
(10x) 
ddH2O to a final 
volume of 1 l 
RT 
 
5 g Sodium 
deoxycholate 
Sigma, Taufkirchen, Germany Sodium deoxycholate (10%) 
ddH2O to a final 
volume of 50 ml 
RT 
 
Tetramethylethylenediamine 
(TEMED) 
 4°C Merck, Darmstadt, Germany 
60.57 g Tris Roth, Karlsruhe, Germany 
ddH2O to a final 
volume of 1 l 
 
Tris-HCl (0.5 M) (pH 6.8) 
pH adjusted to 6.8 
RT 
 
12.11 g Tris Roth, Karlsruhe, Germany 
ddH2O to a final 
volume of 100 ml 
 
Tris-HCl (1 M) (pH 6.8) 
pH adjusted to 6.8 
RT 
 
12.11 g Tris Roth, Karlsruhe, Germany 
ddH2O to a final 
volume of 100 ml 
 
Tris-HCl (1 M) (pH 7.4) 
pH adjusted to 7.4 
RT 
 
363.42 g Tris Roth, Karlsruhe, Germany 
ddH2O to a final 
volume of 1 l 
 
Tris-HCl (3 M) (pH 8.8) 
pH adjusted to 8.8 
RT 
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4.1.14.4 Immunofluorescence Staining 
Name Composition Storage Company 
0.25 g BSA  Sigma, Taufkirchen, 
Germany 
Bovine serum albumin 
(BSA) (1%) 
25 ml ddH2O 
4°C 
 
3 ml 37% Formaldehyde Merck, Darmstadt, 
Germany 
Formaldehyde (3%) 
34 ml 1x PBS 
4°C 
 
62.5 µl Triton X-100 Merck, Darmstadt, 
Germany 
Triton X-100 (0.25%) 
25 ml 1x PBS 
4°C 
 
Vectashield® mounting 
medium with DAPI 
 4°C Vector Laboratories, 
Burlingame, USA 
 
4.1.14.5 Molecular Cloning and Transformation 
Name Composition Storage Company 
Agarose (electrophoresis 
grade) 
 RT Invitrogen, Karlsruhe, 
Germany 
250 mg Bromphenol blue AppliChem GmbH, 
Darmstadt, Germany 
33 ml Tris (150 mM) (pH 7.6) Roth, Karlsruhe, 
Germany 
60 ml Glycerol Roth, Karlsruhe, 
Germany 
Agarose probe buffer 
(10x) 
ddH2O to a final volume of 100 
ml 
4°C 
 
20 g Trypton/Pepton Roth, Karlsruhe, 
Germany 
5 g Yeast Extract Roth, Karlsruhe, 
Germany 
0.5 g NaCl Fluka, München, 
Germany 
2.5 ml 1 M KCl Merck, Darmstadt, 
Germany 
10 ml 1 M MgCl2 Merck, Darmstadt, 
Germany 
20 ml 1 M Glucose  
ddH2O to a final volume of 1 l  
SOC medium (pH 7.0) 
Autoclaved 
4°C 
 
3 g Roth, Karlsruhe, 
Germany 
Kanamycin sulphate (30 
mg/ml) 
100 ml ddH2O 
-20°C 
 
20 g Trypton/Pepton Roth, Karlsruhe, 
Germany 
5 g Yeast extract Roth, Karlsruhe, 
Germany 
10 g NaCl Merck, Darmstadt, 
Germany 
ddH2O to a final volume of 1 l  
Lysogeny broth (LB) 
medium (pH 7.0) 
Autoclaved 
4°C 
 
15 g Agar AppliChem GmbH, 
Darmstadt, Germany 
1 l LB Medium  
LB agar 
Autoclaved 
4°C 
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Name Composition Storage Company 
Lipofectamine® 2000 
reagent 
 4°C Invitrogen, Karlsruhe, 
Germany 
RedSafe™ nucleic acid 
staining solution 
 4°C iNtRON 
Biotechnology, 
Kyungki-Do, Korea 
108 g Tris Roth, Karlsruhe, 
Germany 
55 g Boric acid Merck, Darmstadt, 
Germany 
40 ml EDTA (0.5 M)  
TBE buffer (10x) (pH 8.0) 
ddH2O to a final volume of 1 l 
RT 
 
100 ml TBE buffer (10x) (pH 
8.0) 
 TBE buffer (1x) 
900 ml ddH2O 
RT 
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4.2 Methods 
4.2.1 Cell Culture 
4.2.1.1 Cell Culture Conditions 
Cells were cultured in complete medium under standard cell culture conditions in 
incubators with humidified atmosphere containing 7% carbon dioxide (CO2) (pH 7.4) at 
37°C. In all experiments, asynchronously and exponentially growing cells (∼60% 
confluence) were used. 
4.2.1.2 Cell Freezing 
Cell cultures (∼60% confluence) were trypsinised using Trypsin/EDTA 
(trypsinisation time was cell line dependent: 7-15 min), resuspended in complete medium, 
collected in 50 ml Falcon tube and centrifuged (130 rcf, 4°C, 5 min). The supernatant was 
removed and the cell pellet was resuspended in ice-cold freezing medium (T25 Flask: 1 
ml, T75: 3 ml, T175: 6 ml) and transferred into pre-cooled Cryovials (1 ml of the cell 
suspension per Cryovial). Finally, the Cryovials were stored in a -80°C freezer. 
4.2.1.3 Cell Thawing 
Frozen Cryovials were removed from -80°C freezer and warmed by hand until the 
frozen cell suspension melted (∼5 min). The cell suspension was transferred using a 5 ml 
pipette into a sterile T75 flask containing 25 ml complete medium. The medium was 
replaced after 5 h. 
4.2.1.4 Passaging of Cells 
50-70% confluent cell cultures were split into new cell culture flasks. Cells were 
washed once with PBS, trypsinised and resuspended in complete medium. The cell 
suspension was split 1:3-1:30 (splitting ratio was cell line dependent) into a new cell 
culture flask containing fresh complete medium. The new flask was controlled using an 
inverted microscope and placed inside the cell culture incubator. In all experiments, cell 
cultures with a maximum passage number of 12 passages were used to minimise the 
genetic drift. 
4.2.1.5 Cell Counting 
A cell counting chamber (Haemocytometer) was used to count cells in cell 
suspensions. Both the counting slide and the cover slip were carefully cleaned with 70% 
ethanol. The coverslip was moistened by exhaled breath and placed over the counting 
slide. 10 µl of cell suspension were pipetted at the coverslip’s edge and allowed to run 
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between the coverslip and the counting slide. Cells in each of the four large corner 
squares of the Haemocytometer were counted using 10x objective of the inverted 
microscope. The mean cell count per square was calculated and multiplied by 10,000 to 
obtain the total cell count per ml. 
4.2.2 Radiation Exposure 
Cells were irradiated at room temperature (RT) with single doses of X-rays using 
X-ray irradiator (Yxlon Y.TU 320, Yxlon, Copenhagen, Denmark) yielding a dose rate of 
∼1.2 Gy/min at 200 kV and 20 mA. The X-ray radiation was filtered with 0.5 mm copper 
filter. Applied doses ranged from 0 to 8 Gy. The delivered dose was measured using a 
Duplex dosimeter (PTW, Freiburg, Germany). 
4.2.3 Small interfering RNA-mediated Knockdown 
Small interfering ribonucleic acids (siRNAs) are a class of single- or double-
stranded RNA molecules which interfere with the expression of specific target genes with 
complementary nucleotide sequences (Elbashir et al., 2001; Kim et al., 2005). In this 
study, the expression of CDK2 or CDK9 was downregulated using CDK2 or CDK9 
siRNAs. In all experiments, a non-specific siRNA transfection was used as control. 
siRNA transfection was performed in 6-well plates, 60 mm cell culture dishes or 
100 mm cell culture dishes. The number of seeded cells was cell line dependent (Table 
 4.1). 
 
Table  4.1. The number of seeded cells 24 h prior to siRNA transfection 
Seeded number of cells Cell line 
6-well plate 60 mm dish 100 mm dish 
SAS 150,000/Well 80,000 600,000 
FaDu 250,000/Well 80,000 700,000 
HSC4 250,000/Well ----- ----- 
Cal33 250,000/Well ----- ----- 
UTSCC5 300,000/Well ----- ----- 
UTSCC8 400,000/Well ----- ----- 
 
Twenty-four hours after seeding the cells, the siRNA/Opti-MEM® I mixture (Mixture 
A) and Oligofectamine/Opti-MEM® I mixture (Mixture B) were prepared and incubated for 
10 min at RT. Both mixtures (A and B) were pooled together and incubated for 20 min at 
RT (Table  4.2). 
Seeded sells (30-50% confluent) were washed once with Opti-MEM® I (6-well: 1 
ml/Well, 60 mm dish: 1.5 ml, 100 mm dish: 6 ml) and fresh Opti-MEM® I (6-well: 800 
µl/Well, 60 mm dish: 1.2 ml, 100 mm dish: 4.8 ml) was added to the cells. siRNA mixture 
Materials and Methods 
32 
 
was added to the cells (6-well: 200 µl/Well, 60 mm dish: 300 µl, 100 mm dish: 1.2 ml). 
After 8 h incubation at standard cell culture conditions, Opti-MEM® I containing 20% FBS 
was pipetted to the transfected cells (6-well: 1 ml/Well, 60 mm dish: 1.5 ml, 100 mm dish: 
6 ml). The transfected cell cultures were used for colony formation assay (Section  4.2.4), 
γH2AX/53PB1 foci assay (Section  4.2.5), apoptosis assay (Section  4.2.6), cell cycle 
analysis (Section  4.2.7) and protein analysis (Section  4.2.8). 
 
Table  4.2. Dilution scheme of siRNA transfection mixture. 
Mixture A Mixture B Tissue 
culture 
vessel 
Initial 
siRNA 
conc. 
Final 
siRNA 
conc. Required amount 
of siRNA 
Required 
amount 
of Opti-
MEM® I 
Required 
amount of 
Oligofectamine 
Required 
amount 
of Opti-
MEM® I 
Total 
volume
1 well 
in 6-
well 
plate 
20 µM 20 nM 1 µl 184 µl 4 µl 11 µl 200 µl 
60 mm 
dish 
20 µM 20 nM 1.5 µl 276 µl 6 µl 16.5 µl 300 µl 
100 mm 
dish 
20 µM 20 nM 6 µl 1104 µl 24 µl 66 µl 1.2 ml 
 
4.2.4 Colony Formation Assay  
Colony formation assays were applied for the measurement of clonogenic cell 
survival. This assay is based on the ability of a single cell to undergo at least 5-6 
successive divisions and grow into a colony as published (Palyi et al., 1995; Puck & 
Marcus, 1956; Storch et al., 2010). 
4.2.4.1 Two Dimensional (2D) Colony Formation Assay 
Single cells were seeded in polystyrene 6-well plates (Cordes et al., 2006). Cells 
were washed with 1x PBS, trypsinised, resuspended in complete medium and counted. 
Volume X (Equation  4.1) of the cell suspension was diluted in 5 ml complete medium in a 
50 ml Falcon tube to obtain a 20,000 cell/ml single cell suspension. 
 
100,000   
X = 
Total cell count  Equation  4.1 
 
The required number of cells was seeded in each well of the 6-well plate as 
indicated in Table  4.3. Two ml of complete medium were added into each well. The plates 
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were shaken back-and-forth and right-to-left to ensure the uniform distribution of cells in 
each well. The cell distribution was microscopically controlled. 
After 24 h, the plates were irradiated with a single dose of X-rays (0, 2, 4, 6 or 8 
Gy) at RT. After the specific incubation time (Table  4.3), the colony formation assay was 
stopped by fixing the cells with 80% ethanol for 10 min. The fixed cells were stained for 1 
h with Coomassie blue stain. Finally, the 6-well plates were washed with running tap water 
and dried at RT. 
 
Table  4.3. The optimal number of cells and the corresponding incubation times for 
colony formation assays. 
Number of cells per X-ray dose 
(Volume of 20,000/ml cell suspension) 
Cell line 
0 Gy 2 Gy 4 Gy 6 Gy 8 Gy 
Incubation time
(Days after 
plating) 
WT MEF 1250 
(62.5 µl) 
1250 
(62.5 µl) 
2500 
(125 µl) 
5000 
(250 µl) 
6200 
(310 µl) 
7 
CDK2-/- MEF 1250 
(62.5 µl) 
1250 
(62.5 µl) 
2500 
(125 µl) 
5000 
(250 µl) 
6200 
(310 µl) 
7 
SAS 700 
(35 µl) 
700 
(35 µl) 
1400 
(70 µl) 
2800 
(140 µl) 
3200 
(210 µl) 
7 
FaDu 1000 
(50 µl) 
1000 
(50 µl) 
2000 
(100 µl) 
4000 
(200 µl) 
6000 
(300 µl) 
11 
HSC4 1000 
(50 µl) 
1000 
(50 µl) 
2000 
(100 µl) 
4000 
(200 µl) 
6000 
(300 µl) 
8 
Cal33 1200    
(60 µl) 
1200   
(60 µl) 
2400 
(120 µl) 
4800 
(240 µl) 
7200   
(360 µl) 
13 
UTSCC5 1500    
(75 µl) 
1500   
(75 µl) 
3000 
(150 µl) 
6000 
(300 µl) 
9000   
(450 µl) 
14 
UTSCC8 2000  
(100 µl) 
2000 
(100 µl) 
4000 
(200 µl) 
8000 
(400 µl) 
12000 
(600 µl) 
14 
SAS-EGFP 700 
(35 µl) 
700 
(35 µl) 
1400 
(70 µl) 
2800 
(140 µl) 
3200 
(210 µl) 
7 
SAS-CDK9-
EGFP 
700 
(35 µl) 
700 
(35 µl) 
1400 
(70 µl) 
2800 
(140 µl) 
3200 
(210 µl) 
7 
 
4.2.4.2 Three Dimensional (3D) Colony Formation Assay 
In 3D colony formation assay, single cells were plated in 0.5 g/l Matrigel™ laminin-
rich extracellular matrix (lrECM)/complete medium mixture in 96-well plates (Hehlgans et 
al., 2008). The wells of the 96-well plate were coated with 50 µl sterile 1% agarose. Cells 
were mixed with the appropriate amount of 0.5 g/l lrECM/complete medium mixture to 
obtain a final cell count of 2000 cell/100 µl and each well was plated with 100 µl of the 
cell/lrECM/complete medium mixture. The plates were incubated in the incubator under 
standard conditions. Three hours later, 100 µl of complete medium was added to each 
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well. To avoid evaporation and dryness, 200 µl of sterile 1x PBS was pipetted to the 
empty wells around the wells in which cells were seeded. 
After 24 h, cells were irradiated and incubated for seven days (SAS) or nine days 
(FaDu). Formed colonies were fixed by adding 100 µl of 3% formaldehyde in 1x PBS into 
each well. 
4.2.4.3 Evaluation of Colony Formation Assay 
The number of colonies formed under 2D conditions was counted using binuclear 
microscope. Under 3D conditions, formed colonies were counted using an inverted 
microscope. Only colonies of more than 50 cells were scored as viable colonies.  
Plating efficiencies (PEs) were calculated by dividing the number of colonies the 
originate from single cells by the number of seeded cells (Equation  4.2). The plating 
efficiency varied between the cell lines. 
 
Number of colonies   PE = Number of seeded cells  Equation  4.2 
 
The surviving fraction (SF) of each irradiation dose was calculated by dividing the 
PE of irradiated cells by the PE of unirradiated cells according to Equation  4.3. 
 
PEirradiated   SF = PEunirradiated  Equation  4.3 
 
Representative images of 2D and 3D colony formation were acquired using an 
Epson Perfection 4490 PHOTO scanner (Epson, Meerbusch, Germany) or using an 
Axiovert 40 CFL microscope (Zeiss, Jena, Germany) respectively. Each point on the 
survival curves represents the mean surviving fraction ± standard deviation from three 
independent experiments. 
4.2.5 γH2AX/53BP1 Foci Assay 
γH2AX/53BP1 foci assay was performed to evaluate the number of radiation-
induced γH2AX and p53 binding protein 1 (53BP1) colocalised foci at sites of DNA DSBs 
(Kinner et al., 2008; Rothkamm & Lobrich, 2003). 
γH2AX/53BP1 foci assay was performed by seeding certain number of cells (SAS: 
150,000, FaDu: 300,000) in T25 flasks. After 24 h, cells were irradiated with a single dose 
of X-rays (0 or 6 Gy) and incubated under standard cell culture conditions. Twenty-four 
hours after irradiation, cells were trypsinised, harvested in 5 ml complete medium in a 15 
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ml falcon tube, centrifuged (130 rcf, 4°C, 3 min) and fixed by resuspending the cell pellet 
in 0.5 ml 3% formaldehyde in 1x PBS and stored at 4°C until analysis. 
γH2AX/53BP1-positive nuclear foci of 50 cells were counted using the Axioscope 2 
plus fluorescence microscope (Zeiss, Jena, Germany) and defined as residual DSBs. 
4.2.5.1 Immunofluorescence Staining 
Fixed cell suspension was washed by adding 4 ml 1x PBS and centrifuged (200 
rcf, 4°C, 5 min). The supernatant was removed carefully using a suction pump. The pellet 
was resuspended in 1 ml 0.25% Triton X-100 and incubated at RT for 10 min. In order to 
remove excess Triton X-100, cell suspension was washed by adding 4 ml 1x PBS and 
centrifuged (200 rcf, 4°C, 5 min). The supernatant was discarded and the pellet was 
resuspended in 100 µl 1% PBSA (Blocking, 1 h, RT). Cells were centrifuged (200 rcf, 4°C, 
5 min), and the supernatant was carefully removed using a 100 µl Pipette.  
All antibodies were diluted in 1% PBSA. The 1st primary antibody against γH2AX 
was added for 2 h at RT. Cells were washed by adding 5 ml 1x PBS and centrifuged (200 
rcf, 4°C, 5 min). The supernatant was discarded and the 1st secondary Alexa Fluor anti-
mouse (red) antibody was added (1 h, RT, dark). After washing with 5 ml 1x PBS and 
centrifugation (200 rcf, 4°C, 5 min), the supernatant was removed and cells were stained 
with the second antibody against 53BP1 (1 h, RT, dark). Cells were washed with 5 ml 1x 
PBS, centrifuged to discard the supernatant and incubated with the 2nd secondary Alexa 
Fluor anti-rabbit (green) antibody (1 h, RT, dark). Finally, 5 ml 1x PBS were added and 
followed by centrifugation and removal of the supernatant. The samples were stored in 
dark refrigerator at 4°C. 
4.2.5.2 Mounting of stained Cells on Glass Slides 
Stained cells were fixed on slides using a 100 µl pipette. After resuspending the 
pellet, 7 µl of cell suspension were spread on a microscopic glass slide using a 100 µl 
pipette tip. A small drop of Vectrashield® fluorescence specialised mounting media 
containing 4',6-diamidino-2-phenylindole (DAPI) was added and mounted by a cover slip. 
The slides were then stored in dark at -20°C. 
4.2.5.3 Evaluation of γH2AX/53BP1 positive Foci 
The evaluation was carried out using an Axioskop 2 plus fluorescence microscope 
(Zeiss, Jena, Germany). The number of γH2AX/53BP1 positive foci was defined in nuclei 
of 50 cells (foci-free nuclei were also counted). The mean number of foci per cell was 
evaluated as described in (Eke et al., 2007). Data were expressed as means ± standard 
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deviation of three independent experiments. Representative fluorescence images were 
obtained using a LSM 510 Meta equipped with Zeiss LSM 510 Software (Zeiss). 
4.2.6 Apoptosis assay 
For analysing apoptosis, transfected cells were irradiated with X-rays (0 or 6 Gy, 
single dose). Twenty-four hours later, cells were trysinised and mounted with 
Vectashield/DAPI mounting medium. Apoptotic nuclei of 100 cells were counted using the 
Axioscope 2 plus fluorescence microscope (Zeiss, Jena, Germany). 
4.2.7 Cell Cycle Analysis 
BrdU is a thymidine base analogue that is able to incorporate into the newly 
synthesised DNA during the S phase of the cell cycle (Ross et al., 2008). Incorporated 
BrdU into cellular DNA was detected using specific anti-BrdU/FITC antibodies and the S 
phase cell population was distinguished. The total DNA content of cells was stained with 
propidium iodide (PI). 
4.2.7.1 Cell Cycle Analysis after Irradiation with X-rays 
Cells were seeded in a 100 mm cell culture dish (MEFs: 150,000, SAS: 40,000 
cell/dish, FaDu: 45,000 cell/dish), and after 72 h were irradiated with X-rays (0 or 6 Gy). At 
certain time points after irradiation (0, 10, 14, 18, 24 or 48 h), cells were pulse-labelled 
with 10 µM BrdU in complete medium (10 min, 37°C). The BrdU-containing medium was 
discarded, and cells were washed twice with 1x PBS and trypsinised. Cell suspension was 
collected in a 15 ml Falcon tube and centrifuged (150 rcf, 4°C, 8 min). The cell pellet was 
resupended in 1 ml of -20°C-cold 80% ethanol (added drop by drop with vortex) and 
stored at -20°C until analysis. 
4.2.7.2 Cell Cycle Analysis after CDK2 or CDK9 Depletion 
Cells were seeded in a 60 mm cell culture dish (SAS: 80,000 cell/dish, FaDu: 
80,000 cell/dish). After 24 h, cells were transfected with CDK2 or CDK9 siRNAs. At 0, 1, 
2, 3 or 4 days after transfection, cells were treated with 10 µM BrdU, fixed in -20°C-cold 
80% ethanol and stored at -20°C until analysis. 
4.2.7.3 Cell Cycle Analysis after CDK2 or CDK9 Knockdown combined 
with Irradiation 
Cells were plated in a 60 mm cell culture dish (SAS: 80,000 cell/dish, FaDu: 
80,000 cell/dish) and after 24 h were transfected against CDK2 or CDK9. Later, 0 or 6 Gy 
single dose of X-rays was applied 24 h after transfection. Fourteen hours later, cells were 
pulse-labelled with 10 µM BrdU, fixed in -20°C-cold 80% ethanol and stored at -20°C until 
analysis. 
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4.2.7.4 Extraction of Nuclei and Immunofluorescence Staining 
Extraction of nuclei was performed as described in (Cordes et al., 2006). Cells 
were centrifuged (150 rcf, 4°C, 8 min) and the pellet was resuspended in 2 ml of 0.01% 
RNase solution (shaking, 37°C, 10 min). After re-centrifugation, the pellet was 
resuspended in 2 ml of freshly prepared 0.05% pepsin solution (shaking, 37°C,10 min) 
and incubated for 5 min in ice. Next, 4 ml of 1x PBS were added to the cell suspension 
followed by centrifugation. Extraction of cell nuclei was accomplished by resuspending the 
pellet in 2 ml of 2N HCl for 10 min. Cell nuclei were washed by adding 4 ml of cold 1x PBS 
and centrifugation (repeated twice). Nuclei were resuspended in PBSA, centrifuged and 
incubated with 200 µl of 1:10 anti-BrdU (dark, RT, 30 min). After PBS washing and 
centrifugation, the sample was resuspended in 200 µl of FITC-conjugated anti-mouse IgG 
antibody (dark, RT, 30 min). Finally, the total DNA content was stained by 1 ml of 25 µg/ml 
PI solution (dark, 1 h). 
Using a CyFlow flow cytometer, the following parameters were recorded for each 
sample: size of nuclei [Forward scatter, FSC], granularity of nuclei [Side scatter, SSC], 
BrdU-FITC [FL1], total DNA content (PI) [FL3]. 
Using the FloMax software, a dot blot of FL1 (logarithmic scale) on the y axis and 
FL3 (linear scale) on the x axis was generated and gated to obtain the cell cycle 
distribution of the sample as shown in Figure  4.1. 
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Figure  4.1. Flow cytometric cell cycle analysis. Dot blot showing the proportion of BrdU-
FITC [FL1] positive cells as a function of PI [FL3]. Proportions of different cell cycle phases 
were defined and calculated as a percentage of the total count of events. 
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4.2.8 Protein Analysis 
4.2.8.1 Western Blot Analysis after CDK2 Knockdown 
Transfected cells were seeded in 100 mm cell culture dishes (1.2 million cell/dish). 
After 24 h, whole cell lysates were prepared by harvesting cells in modified 
Radioimmunoprecipitation Assay (RIPA) lysis buffer. These lysates were used to monitor 
the level and phosphorylation status of a panel of cell cycle- and transcription-related 
proteins. 
4.2.8.2 Western Blot Analysis of DNA Damage Response Protein after 
CDK2 or CDK9 Knockdown combined with Irradiation 
In order to investigate the effects of depletion of CDK2 or CDK9 on DNA damage 
response proteins, transfected cell cultures were irradiated with 0 or 6 Gy single dose of 
X-rays and whole cell lysates were prepared 15 min after irradiation. 
4.2.8.3 Protein Kinetic Analysis after CDK9 Knockdown 
Cells were seeded in 60 mm cell culture dishes (SAS: 100,000 cell/dish, FaDu: 
150,000 cell/dish) and transfected after 24 h. At certain time points (0, 12, 24 and 48 h), 
cells were harvested in modified RIPA lysis buffer and total cell lysates were prepared. 
Cell lysates were subjected to SDS-PAGE and immunoblotted with antibodies against cell 
cycling and transcription related proteins. 
4.2.9 Total Protein Extraction 
Protein lysates were prepared from adherent cell cultures in 60 mm or 100 mm 
dishes. After placing the dishes on an ice-cold metal plate, the cell culture medium was 
discarded and cells were washed twice with ice-cold 1x PBS. 80 μl (for 60 mm dish) or 
200 μl (for 100 mm dish) of modified RIPA buffer were pipetted to the cells. Next, cells 
were scraped off the dish using a cell scraper and cell lysate was collected in a 1.5 ml 
Eppendorf tube. After 30 min incubation on ice, cell lysate was forced through a small 
needle (4 times) using an insulin syringe. The sample was incubated for 1 h on ice and 
centrifuged (16000 rcf, 20 min, 4°C). The supernatant was transferred into a new ice-cold 
1.5 ml Eppendorf tube and stored in -80°C freezer. 
4.2.10 Determination of Protein Concentration  
For accurate determination of protein concentration, the Pierce® Bicinchoninic Acid 
(BCA) Protein Assay Kit was used (Hehlgans et al., 2008). In this assay, protein samples 
were diluted 1:10 in RIPA solution (2 µl of sample in 18 µl of RIPA solution). Protein 
standards of 0.025, 0.5, 1.0, 2.0 mg/ml of bovine serum albumin (BSA) were prepared. 
Standards and unknown samples were pipetted into 96-well plate (flat bottom). BCA 
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working reagents were mixed 50 parts of BCA Reagent A with 1 part of BCA Reagent B 
(50:1, Reagent A:B). 200 µl of the working reagent mixture was then added to each 
sample and the plate was incubated at 37°C. After 30 min incubation time, the 
absorbance of the loaded samples was measured using a TECAN microplate reader 
(Excitation filter: 560 nm) and the Magellan 5.0 software. 
4.2.11 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SDS-PAGE is a technique used to separate charged protein molecules through a 
gel matrix using an electric current. These charged protein molecules migrate by different 
rates through the gel matrix according to size, charge and shape (Frederick et al., 2002). 
SDS-PAGE was performed using Hoefer SE 250 Mini-Gel System with a 1.5 mm 
comb. After assembling the gel sandwich, 6.9 ml of ice-cold resolving gel mixture was 
casted inside, covered by a layer of isopropanol and allowed to gelatinise at RT. Twenty 
minutes later, the isopropanol layer was discarded, and the gel surface was washed three 
times with double distilled water (ddH2O) and dried. After drying, the 1.5 mm comb was 
inserted and 1.5 ml of ice-cold 5% stacking gel mixture was loaded and allowed to 
gelatinise. Gel-forming mixtures with different acrylamide concentrations were prepared 
according to the formulations given in Table  4.4. 
Before loading the samples, the gel comb was removed and the slots were 
washed three times with 1x running buffer. 
 
Table  4.4. Composition of resolving and stacking gels. 
Resolving gel Components (ml) 
4% 8% 10% 
Components (ml) Stacking gel (5%) 
ddH2O 4.52 3.46 2.93 ddH2O 1.63 
Tris-HCl (3M) pH 8.8 2.00 2.00 2.00 Tris-HCl (0.5 M) pH 
6.8 
0.72 
Acrylamide (30%) 1.06 2.13 2.67 Acrylamide (30%) 0.50 
Glycerol (50%) 0.16 0.16 0.16 Glycerol (50%) 0.06 
SDS (10%) 0.08 0.08 0.08 SDS (10%) 0.03 
APS (10%) 0.16 0.16 0.16 APS (10%) 0.06 
TEMED 0.0064 0.0064 0.0064 TEMED 0.0048 
 
The separation of proteins was performed by applying a constant electric current of 
30 mA/Gel for ∼2 h. 
4.2.11.1 Sample Preparation and Loading 
20-25 µg of protein were mixed with 3 µl of loading buffer (6x) and denatured by 
heating at 90°C for 5 min. After short centrifugation (3 sec, 16000 rcf), the sample was 
loaded into the gel slot using a Microliter™ syringe.  
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4.2.12 Western Blotting 
Using Western blotting, SDS-PAGE separated protein bands were 
electrophoretically transferred to an immobilising membrane. A semi-dry transfer unit was 
used to transfer proteins to a nitrocellulose membrane (Hehlgans et al., 2008). 
After SDS-PAGE, the polyacrylamide gel sandwich was disassembled and 
covered by a transfer buffer-wetted nitrocellulose membrane and three pieces of transfer 
buffer-wetted Whatman filter papers. The other side of the polyacrylamide gel was 
covered by three transfer buffer-wetted Whatman filter papers, and the sandwich was 
gently squeezed on both sides to get red of the air bubbles. The sandwich was placed on 
the blotter (the nitrocellulose membrane side of the sandwich was placed on the positive 
(anode) plate). The transfer of proteins was performed by applying a constant electric 
current (0.8 mA/cm2 nitrocellulose membrane) for 3 h. 
After blotting, the membrane was washed twice with ddH2O and rinsed in Ponceau 
S solution for 1 min to visualise the protein bands. The stained membrane was washed 
again with ddH2O and after the molecular weight bands of Benchmark™ protein ladder 
were marked, the membrane was scanned using Epson Perfection 4490 PHOTO scanner. 
4.2.13 Immunodetection 
The membrane was cut into smaller stripes of desired range of molecular weight. 
The Benchmark™ protein ladder bands served as a molecular weight reference. The 
desired stripe was destained from Ponceau S using 1x PBS and blocked with 5% milk 
buffer (agitated, 30 rpm, 1 h). The blocked membrane stripe was welded together with the 
desired primary antibody in an air bubble-free thin plastic foil and incubated overnight at 
4°C (agitated, 10 rpm). Later, the membrane stripe was washed three times (10 min each) 
with PBST and incubated with the horseradish peroxidase (HRP)-conjugated secondary 
antibody (agitated, 10 rpm, RT, 1.5 h). 
The membrane stripe was washed five times with PBST and once with PBS (10 
min each). The HRP activity of the membrane-attached secondary antibody was observed 
using SuperSignal® West Dura Extended Duration substrate kit. The two reagents of the 
kit were mixed together in equal ratios and slowly pipetted over the membrane stripe (0.05 
ml substrate mixture per cm2 of the membrane stripe). After 3 min, the substrate mixture 
was discarded and the stripe was placed between two transparent pieces of foil in an X-
ray detection cassette. The chemiluminescent signal was detected using Amersham 
Hyperfilm ECL X-ray films in a red lightened dark room. Films were developed with Kodak 
GBX developer, fixed in Kodak GBX fixer, rinsed in tap water and dried. 
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4.2.14 Analysis of Protein Expression 
The X-ray films were scanned using Epson Perfection 4490 PHOTO scanner and 
the intensities of protein bands were analysed by ImageJ (Version 1.47g) software. The 
measured intensity values of detected protein bands were normalised to the intensity 
values of β-actin. The relative phosphorylation ratio of a protein was calculated by 
normalising the intensity value of phospho-protein versus total protein. 
4.3 Synthesis of recombinant DNA and Molecular Cloning 
The construction of recombinant DNA and molecular cloning were performed 
according to (Sambrook, 2001) or according to the manufacturer's protocols of used kits. 
4.3.1 Polymerase Chain Reaction 
Amplification of human CDK9 (hCDK9) gene sequence (PCR product: 1119 bp) 
was performed using HotStarTaq® Plus Polymerase. PCR reaction mixture consisted of: 2 
µl 10x PCR amplification buffer, 1 µl dNTPs, 1 µl hCDK9-NheI forward primer, 1 µl 
hCDK9-BamHI reverse primer, 0.6 µl MgCl2, 2 µl of DNA, 0.4 µl HotStarTaq® Plus 
Polymerase and 12 µl ddH2O were mixed in a thin-walled PCR tube. Placental DNA 
(UKD, Dresden, Germany) was used as a template for PCR amplification. The optimal 
annealing temperature (Ta = 64°C) was determined by a gradient-PCR. The PCR started 
with a single denaturing cycle (4 min, 95°C), 35 cycles (30 sec, 95°C; 45 sec, 64°C; 45 
sec, 72°C); single extension phase (5 min, 72°C), reaction hold at ∞ 4°C. The PCR 
product size was analysed by agarose gel electrophoresis. 
4.3.2 Agarose Gel Electrophoresis 
To check whether the PCR generated the desired DNA fragment, agarose gel 
electrophoresis was used to separate the PCR products.  
DNA samples were mixed with agarose probe buffer (10x) and loaded into 1% 
agarose gel containing RedSafe™ nucleic acid stain. Loaded DNA samples were 
electrophoretically separated at 160 V for 1 h. The gel was placed on a UV-
Transilluminator and the image was acquired using a Bio Imaging System. The captured 
image was printed out and saved as an image file. 
The presence of the PCR product of expected size (1.1 kb, the size of the coding 
sequence of hCDK9) was verified by comparing the size of fractionated PCR product DNA 
fragments with a DNA ladder (Figure  4.2). 
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Figure  4.2. RedSafe™-stained PCR products after agarose gel electrophoresis. PCR 
products were separated in RedSafe™-supplemented 1% agarose gel in 1x TBE buffer. The 
gel image indicates successful amplification of hCDK9 target sequence. No amplification was 
present in the -ve control sample. 
 
4.3.3 Restriction Digestion of the PCR Product and pEGFP-N1 
Vector 
The pEGFP-N1 vector and the CDK9 PCR product were digested with NheI and 
BamHI restriction enzymes. The reaction mixture consisted of: 20 µg DNA, 1 µl 100x BSA, 
10 µl 10x NEBuffer 4, 3 µl NheI, 3 µl BamHI, x µl ddH2O (Total volume = 100 µl). 
4.3.4 Purification of Digested DNA Fragments 
Purification of restricted PCR product and pEGFP-N1 vector was performed 
according to PCR clean-up protocol from Macherey-Nagel using NucleoSpin® Extract II 
Kit. 
4.3.5 Ligation 
Purified digested PCR hCDK9 fragments and pEGFP-N1 vectors were ligated to 
form the new recombinant hCDK9-pEGFP-N1 plasmids (Figure  4.3). The ligation mixture 
composed of: 1 µl purified digested hCDK9 DNA, 2 µl purified digested pEGFP-N1 
plasmid DNA, 1 µl 10x ligation buffer, 10 µl T4 DNA ligase, 5 µl ddH2O. The ligation 
mixture was incubated for 4 h at 14°C in the PCR cycler. 
4.3.6 Transformation 
Introduction of the recombinant DNA into the competent bacterial cells was 
performed through a heat shock. Frozen bacterial cells were thawed on ice and 2 µl of 
plasmid DNA were mixed with bacteria. After 30 min incubation on ice, the transformation 
mixture was incubated at 42°C for 45 sec. The mixture was incubated again on ice. After 2 
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min, 450 µl of SOC medium were added and the transformation mixture was shaken at 
37°C for 2 h. The transformed bacteria were plated on kanamycin (Roth, Karlsruhe, 
Germany) (30 µg/ml) containing agar plates, spread using a sterile spreader and 
incubated overnight at 37°C. 
 
 
Figure  4.3. Vector map of the hCDK9-pEGFP-N1 plasmid. This verctor is generated by 
cloning the coding sequence of CDK9 gene into pEGFP-N1 plasmid (Invitrogen, Karlsruhe, 
Germany). 
 
4.3.7 Plasmid Preparation 
Selection of positive clones was established by culturing single clones from the 
transformed-bacteria agar plates in SOC medium containing antibiotic. Single clones were 
picked up using a sterile pipette tip and grown in 5 ml SOC medium containing 30 µg/ml 
kanamycin (Roth, Karlsruhe, Germany) in 15 ml Falcon tubes. The Falcon tubes were 
incubated at 37°C in the shaking incubator for 8 h (Starter culture). Plasmid preparation 
was performed using the NucleoSpin® Plasmid Kit according to manufacturer’s 
instructions. In order to prepare a large amount of the plasmid DNA, 1 ml of ready 
prepared starter culture was inoculated into 200 ml SOC medium containing kanamycin 
(Roth, Karlsruhe, Germany) (30 µg/ml) in an Erlenmeyer flask and incubated at 37°C 
overnight in the shaking incubator (Overnight culture). 
Next day, the overnight culture was centrifuged (10 min, 394 rcf, 4°C). The 
supernatant was discarded and the plasmid DNA was isolated according to the 
manufacturer’s protocol using the NucleoBond® AX from Macherey-Nagel. 
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4.3.8 Determination of DNA Concentration 
The plasmid DNA concentration was determined using NanoDrop® spectrometer 
(PeqLab Biotechnologie GmbH, Erlangen, Germany) and ND-1000 software (Version 
3.3.0). 
4.3.9 Sequencing 
The sequence of plasmid DNA was determined by Eurofins MWG Operon 
sequencing department (Martinsried, Germany) and evaluated using the Gap4 program. 
4.3.10 Linearisation of Plasmids  
Both hCDK9-pEGFP-N1 and pEGFP-N1 plasmids were linearised using ApaLI 
restriction enzyme before stable transfection. The reaction mixture consisted of: 20 µg 
DNA, 1 µl 100x BSA, 10 µl 10x NEBuffer 4, 3 µl ApaLI, x µl ddH2O (Total volume = 100 
µl). 
4.4 Stable Transfection 
Stable transfection was used to permanently integrate the hCDK9-pEGFP-N1 
expression vector or pEGFP-N1 empty vector into the genome of SAS HNSCC cells. 
Plasmid DNA transfer was performed using the lipid-based gene delivery reagent 
Lipofectamine™. Stably transfected cells were selected using G418 (Hehlgans et al., 
2009; Sambrook, 2001; Storch, 2010). 
SAS cells were trypsinised, counted and 100,000 cell/well were seeded in 1 ml 
complete medium in a 12-well plate. Plated cells were cultured at standard condition in a 
cell culture incubator. After 24 h, cells were transfected using a stable transfection mixture 
that was prepared as described in Table  4.5. The linearised plasmid DNA/Opti-MEM® I 
mixture A and Lipofectamine™/Opti-MEM® I mixture B were prepared and incubated at 
RT. After 5 min, both mixtures (A and B) were pooled together and incubated for 20 min at 
RT. 
 
Table  4.5. Dilution scheme of stable transfection mixture. 
Mixture A Mixture B Plasmid Initial 
plasmid 
DNA 
conc. 
Required 
amount 
of DNA 
(2 µg) 
Required 
amount of 
Opti-MEM® I
Required 
amount of 
Lipofectamine™ 
Required 
amount of 
Opti-MEM® I
pEGFP-N1 empty 
vector 
(linearised) 
0.857 
µg/µl 
2.3 µl 125 µl 5 µl 125 µl 
hCDK9-pEGFP-N1 
(linearised) 
0.929 
µg/µl 
2.2 µl 125 µl 5 µl 125 µl 
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After changing the medium, 250 µl of the transfection mixture was pipetted to the 
cells and the medium was replaced again after 5 h with fresh complete medium. Twenty-
four hours after transfection, cells in each well were trypsinised and equally split into five 
100 mm dishes under selection pressure in complete medium containing 1.5 mg/ml G418. 
Untransfected SAS cells were seeded in 100 mm dish in complete medium containing 1.5 
mg/ml G418 and were used as control for selection. All cells in the 100 mm control dish 
died within 8 days after treatment with G418. The G418-resistant transfected cells were 
found growing into colonies, and were isolated using sterile cloning cylinders 16 days after 
transfection. Each isolated clone was transferred to a well in a 24-well plate and grown in 
complete medium containing 1.5 mg/ml G418. The medium was routinely changed every 
3-4 days. A glass cover slip seeded with cells was prepared for each single clone. These 
cover slips were examined using the Axioscope 2 plus fluorescence microscope (Zeiss, 
Jena, Germany) to control the transfection efficiency of isolated clones. 
Positive clones (with more than 80% EGFP positive cells) were identified, and the 
levels of exogenous expression of CDK9 and EGFP were controlled for each single clone 
by Western blot. 
Single positive clones were frozen and stored at -80 C and a pool of three positive 
clones of SAS-CDK9-EGFP cells as well as SAS-EGFP cells was prepared, cultured and 
used for further experiments. 
Fluorescence images of SAS-CDK9-EGFP and SAS-EGFP control cells were 
obtained using LSM 510 Meta equipped with Zeiss LSM 510 Software. Cells were seeded 
for 24 h on glass coverslips and fixed with 3% formaldehyde (10 min). The fixed coverslips 
were mounted with Vectashield/DAPI mounting medium, examined and photographed. 
4.5 Statistical Analysis 
Experimental data were expressed as mean ± standard deviation (s.d.) of three 
independent repeats. The statistical significance of the data was evaluated by Student's   
t-test using Microsoft® Excel 2003. Results were considered statistically significant if the P 
value was less than 0.05. Graphical representations were created using GraphPad Prism 
4.03. 
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5 Results 
5.1 CDK2 Targeting enhances the Radiosensitivity of HNSCC 
Cancer Cells 
Radiotherapy eliminates cancer cells by inducing genetic damage to stop the 
proliferative integrity of cells. CDK2 is involved in regulating cell cycle progression, cell 
cycle checkpoints (G1/S as well as G2/M) and DNA damage repair response (Aleem et 
al., 2004; Deans et al., 2006; Kaldis & Aleem, 2005; Neganova et al., 2011; 
Satyanarayana & Kaldis, 2009b; Sherr & Roberts, 2004). These functions are essential for 
maintaining genomic integrity and cell survival. Therefore, we investigated the role of 
CDK2 in the cellular radiosensitivity. CDK2-/- and WT MEFs as well as six human HNSCC 
cell lines were used. 
5.1.1 CDK2 Deficiency is associated with increased 
Radiosensitivity in MEFs 
To examine whether CDK2 is involved in cellular radiation survival of MEFs, we 
performed 2D colony formation assays using CDK2-/- and WT MEFs and measured the 
clonogenic survival upon irradiation using 2D colony formation assay. CDK2 deficiency 
was confirmed by Western blotting (Figure  5.1A). Our results showed a significant (P < 
0.05) dose dependent decrease in the clonogenic survival fraction of irradiated CDK2-/- 
MEFs as compared to WT MEFs (Figure  5.1B) (Soffar et al., 2013). 
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Figure  5.1. CDK2 deficiency mediates increased radiosensitivity relative to CDK2 WT 
status. CDK2-/- and WT MEFs were plated for colony formation and irradiated with X-rays (0 - 
8 Gy, single dose) after 24 h. After 7 days, formed colonies were fixed, stained and counted. 
(A) Western blot of CDK2 in CDK2-/- and WT MEF cultures.  β-actin served as loading control. 
(B) Clonogenic survival of irradiated CDK2-/- and WT MEFs. Results show mean ± s.d. (n = 3; 
student’s t-test; * P < 0.05; + P < 0.01). (Soffar et al., 2013). 
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5.1.2 Absence of CDK2 correlates with elevated Number of residual 
DSBs in MEFs 
Several studies suggested that the main target for biological effect of irradiation is 
DNA (Hall & Giaccia, 2006; Han & Yu, 2010). Among different types of radiation-induced 
DNA lesions, DSBs are considered as one of the most severe forms of DNA damage and 
are lethal to cells if left unrepaired (Shaheen et al., 2011; Symington & Gautier, 2011). In 
order to investigate whether CDK2 deficiency affects DNA damage repair of DSBs, we 
performed γH2AX/53BP1 foci assay 24 h after irradiation. Visual γH2AX/53BP1-positive 
foci were defined as residual DSBs (Figure  5.2A). The mean number of γH2AX/53BP1-
positive foci per cell was evaluated. Our results showed a significant (P < 0.05) increase in 
the number of residual DSBs in 6 Gy-irradiated CDK2-/- MEFs relative to WT MEFs 
(Figure  5.2B) (Soffar et al., 2013). 
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Figure  5.2. CDK2-/- MEFs show elevated number of radiation-induced residual DSBs as 
compared to WT MEFs. CDK2-/- and WT MEFs were plated and irradiated with X-rays (0 or 6 
Gy, single dose). After 24 h, cells were harvested, fixed and immunostained against γH2AX 
and 53BP1. DAPI was used to stain nuclei. Double stained foci from 50 cell nuclei were 
counted by fluorescence microscopy and defined as residual DSBs. (A) Representative 
photographs of γH2AX/53BP1 double immunofluorescence staining. γH2AX (red), 53BP1 
(green), DAPI (blue). Bar, 10 μm. (B) Number of γH2AX/53BP1-positive colocalised foci per 
cell 24 h after radiation. Results show mean ± s.d. (n = 3; student’s t-test; * P < 0.05). (Soffar et 
al., 2013). 
 
5.1.3 Loss of CDK2 mediates elevated Radiation-induced G2/M 
Phase Blockage 
Activation of cell cycle checkpoints functions primarily to arrest cells transiently 
after genotoxic stress which provides sufficient time for DNA damage repair 
(Satyanarayana et al., 2008; Weinert et al., 1994; Weitzman et al., 2013; Yata & Esashi, 
2009). As CDK2 is involved in cell cycle progression and checkpoint response, we 
performed cell cycle analysis to investigate whether CDK2 deficiency in MEFs affects cell 
cycle progression or cell cycle checkpoint response upon irradiation. In comparison to 
unirradiated controls, our results displayed a radiation-induced G2/M cell cycle phase 
arrest that peaks 10 h after irradiation in CDK2-/- MEFs as well as WT MEFs (differences 
between irradiated and unirradiated data points were statistically significant (P < 0.05) at 
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10, 14 and 18 h after irradiation) (Figure  5.3A). In parallel, we observed a significant (P < 
0.05) decrease in S phase populations. In addition, our results revealed a slight but 
significant (P < 0.05) increase in the G1 phase populations 24 h after irradiation. 
Comparing cell cycle distribution of unirradiated CDK2-/- to WT MEFs (0 h time point 
shown in Figure  5.3A) revealed that CDK2-/- MEFs possess significantly (P < 0.01) lower 
G1 phase and higher S phase populations as compared to WT MEFs (Figure  5.3B). In 
Figure  5.3C, we compared the cell cycle distribution of CDK2-/- to WT MEFs 10 h after 
irradiation (the time point at which the radiation-induced cell-cycle effects reached 
maximum). Interestingly, irradiation of CDK2-/- MEFs resulted in a significant (P < 0.05) 
increase in the percentage of cells accumulating in the G2/M phase as compared to WT 
MEFs (Figure  5.3C) (Soffar et al., 2013). 
Taken together, our data suggest a possible role of CDK2 in radiation survival, 
repair of radiogenic DSBs and G2/M phase block in response to irradiation. 
5.1.4 CDK2 Knockdown increases the Radiosensitivity of HNSCC 
Cancer Cells under 2D Growth Conditions 
As CDK2 deficiency modulated the radiosensitivity of MEFs (Figure  5.1), we next 
studied the effect of CDK2 targeting on the cellular response of a panel of HNSCC cell 
lines to irradiation. The investigated cell lines were SAS, FaDu, HSC4, Cal33, UTSCC5 
and UTSCC8. We evaluated the clonogenic survival upon CDK2 knockdown plus/minus 
irradiation using 2D colony formation assay. CDK2 knockdown was performed using two 
different CDK2 siRNAs (CDK2 siRNA#1 and CDK2 siRNA#2). A non-specific siRNA (Co 
siRNA) was used as control. 
Our results displayed efficient CDK2 knockdown via CDK2 siRNA#1 (Figure  5.4A). 
The basal survival fraction of all tested cell lines upon CDK2 silencing was not affected 
(Figure  5.4B). Regarding the clonogenic radiation survival, we observed that SAS and 
FaDu CDK2 knockdown cell cultures are significantly (P < 0.05) more sensitive to X-rays 
as compared to siRNA control cultures (Figure  5.4C). The other tested cell lines (HSC4, 
Cal33, UTSCC5 and UTSCC8) lacked significant enhancement of radiosensitivity after 
CDK2 knockdown (Soffar et al., 2013). 
We confirmed our findings in SAS and FaDu cells by depleting CDK2 using a 
second CDK2 siRNA (#2) (Figure  5.5A). We found that CDK2 knockdown results in an 
unchanged basal survival fraction and significantly (P < 0.05) enhances the 
radiosensitivity of SAS but not FaDu cells as compared to control cultures (Figure  5.5B, C) 
(Soffar et al., 2013). 
Further investigations to evaluate the molecular role of CDK2 on radiation 
response were performed using CDK2 siRNA#1-depleted SAS and FaDu cell cultures. 
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Figure  5.3. Absence of CDK2 in MEFs is associated with elevated radiation-induced 
G2/M arrest. CDK2-/- and WT MEF cultures were irradiated with X-rays (0 or 6 Gy, single 
dose), pulse-labelled with BrdU at certain time points after irradiation (0, 10, 14, 18, 24 or 48 h) 
and fixed. Cell nuclei were extracted, stained with anti-BrdU/FITC and PI and analysed by 
CyFlow flow cytometer and FloMax software. (A) Cell cycle distribution analysis of unirradiated 
CDK2-/- MEFs compared to WT MEFs. Results show mean ± s.d. (n = 3; student’s t-test; * P < 
0.05; + P < 0.01). (B) Cell cycle distribution of unirradiated CDK2-/- MEFs relative to WT MEFs 
at 0 h. Results show mean ± s.d. (n = 3; student’s t-test; + P < 0.01). (C) Cell cycle analysis of 
CDK2-/- MEFs as compared to WT MEFs 10 h after irradiation. Results show mean ± s.d. (n = 
3; student’s t-test; * P < 0.05; + P < 0.01). ((B) and (C) were published in Soffar et al., 2013). 
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Figure  5.4. CDK2 knockdown enhances the radiosensitivity of 2D HNSCC cell cultures. 
CDK2 siRNA#1-transfected and control cultures were plated and after 24 h irradiated with X-
rays (0 - 8 Gy, single dose). After certain incubation time (7 - 14 days, cell line dependent), 
formed colonies were microscopically counted. (A) Western blot analysis of CDK2 from whole 
cell lysates of CDK2 knockdown or control cell cultures. β-actin served as loading control. (B) 
Unaffected basal clonogenic survival of CDK2 knockdown or control cell cultures. Results show 
mean ± s.d. (n = 3; student’s t-test; n.s. not significant). (C) Clonogenic survival of irradiated 
CDK2 knockdown or control cultures. Results show mean ± s.d. (n = 3; student’s t-test; * P < 
0.05; + P < 0.01). (Soffar et al., 2013). 
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Figure  5.5. Depletion of CDK2 by CDK2 siRNA#2 increases the radiosensitivity of SAS 
but not FaDu cell cultures. CDK2 siRNA#2-transfected and control cultures were plated for 
colony formation and irradiated after 24 h with X-rays (0 - 8 Gy, single dose). (A) CDK2 
Western blotting of whole cell lysate of CDK2 and control knockdown cultures. (B) Basal 
survival of CDK2 siRNA#2 knockdown cultures in comparison to control cultures. (C) 
Clonogenic radiation survival of CDK2 siRNA#2-transfected SAS and FaDu cell cultures as 
compared to control siRNA-transfected cultures. Results show mean ± s.d. (n = 3; student’s t-
test; * P < 0.05; + P < 0.01). (Soffar et al., 2013). 
 
5.1.5 Depletion of CDK2 attenuates radiogenic DSB Repair in SAS 
and FaDu Cells 
Our results revealed that CDK2-/- MEFs possess an elevated number of radiogenic 
residual DSBs as compared to WT cells (Figure  5.2). This indicates a possible role of 
CDK2 in DNA damage repair. In order to investigate whether CDK2 knockdown induces a 
similar effect in HNSCC cancer cells, we performed γH2AX/53BP1-positive foci assay and 
scored radiation-induced residual DSBs upon CDK2 knockdown in SAS and FaDu cell 
lines (Figure  5.6A). In line with our results from the colony formation assays, we observed 
a significant (P < 0.05) increase in the number of radiation-induced γH2AX/53BP1-positive 
foci per cell in CDK2 knockdown SAS and FaDu cell cultures as compared to control 
cultures (Figure  5.6B) (Soffar et al., 2013). 
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Figure  5.6. CDK2 knockdown increases the number of residual DSBs of irradiated SAS 
and FaDu cell cultures. CDK2 siRNA#1-transfected and control cultures were irradiated with 
X-rays (0 - 8 Gy, single dose). After 24 h, cells were trypsinised, fixed and immunostained 
against γH2AX and 53BP1. DAPI was used to stain nuclei. Double stained foci from 50 cell 
nuclei were counted by a fluorescence microscope and defined as residual DSBs. (A) 
Representative photographs show γH2AX/53BP1 double staining of unirradiated and irradiated 
CDK2-depleted and control cultures. γH2AX (red), 53BP1 (green), DAPI (blue). Bar, 10 μm. (B) 
Number of γH2AX/53BP1-positive foci per cell of CDK2 knockdown SAS and FaDu cells 
compared to controls. Results show mean ± s.d. (n = 3; student’s t-test; * P < 0.05). (Soffar et 
al., 2013). 
 
The increased number of radiogenic residual DSBs upon CDK2 knockdown in SAS 
and FaDu suggests that CDK2 is involved in DNA damage repair. To clarify this role, we 
investigated, by Western blotting, a panel of proteins involved in checkpoint signalling and 
DNA repair upon CDK2 knockdown 15 min after irradiation (0 or 6 Gy, X-rays, single 
dose) (Figure  5.7A). The 15 min time point was chosen to address the rapid changes in 
expression and phosphorylation of DNA damage repair proteins in response to irradiation. 
Densitometric analysis of Western blot signals of investigated proteins was performed 
using the ImageJ (Version 1.47g) software, and data were blotted as bar graphs in Figure 
 5.7B. All measured data values were normalised to β-actin as loading control, and values 
of phosphorylation levels of proteins were normalised to total protein levels. Despite 
efficient CDK2 knockdown, our results showed no apparent alterations in the levels of 
ATM, phospho-ATM(S1981), DNA-PK, CHK2, phospho-CHK2(T86), RAD50, NBS1 and 
PCNA (Figure  5.7A, B). Thus, these results cannot explain how CDK2 knockdown 
mediates DNA damage repair (Soffar et al., 2013). 
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Figure  5.7. Impact of CDK2 silencing on expression and phosphorylation of DNA 
damage repair proteins. (A) Western blotting of whole cell protein lysates of CDK2 siRNA#1-
transfected and control cultures harvested 15 min after irradiation (0 or 6 Gy, X-rays, single 
dose). β-actin served as loading control. (B) Densitometric analysis of Western blots of Figure 
A shows the fold change of expression or phosphorylation of proteins. Protein expression 
values were normalised to β-actin. Phosphorylation values of proteins were normalised to total 
protein expression. Results show mean ± s.d. (n = 3; student’s t-test; * P < 0.05; + P < 0.01). 
(Soffar et al., 2013). 
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5.1.6 Silencing of CDK2 does not alter Apoptosis in SAS and FaDu 
Cells 
DNA damage, such as DSBs, might induce cell death by activating apoptosis 
(Ciccia & Elledge, 2010). As CDK2 knockdown increased the number of radiogenic 
residual DSBs (Figure  5.6), we next evaluated the level of apoptosis in CDK2-depleted or 
control SAS and FaDu cells in response to ionising radiation. Our results showed that the 
level of apoptosis is very low in unirradiated as well as 6 Gy-irradiated SAS and FaDu cell 
cultures, and that CDK2 knockdown has no significant impact on apoptosis in both 
unirradiated and irradiated cells (Figure  5.8) (Soffar et al., 2013). 
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Figure  5.8. Apoptosis in unirradiated and irradiated CDK2-depleted or control SAS and 
FaDu cell cultures. CDK2 siRNA#1-transfected cells (non-specific siRNA was used as control) 
were irradiated with X-rays (0 or 6 Gy, single dose), fixed and stained with DAPI. The number 
of apoptotic nuclei per 100 cells was evaluated using fluorescence microscopy. Results show 
mean ± s.d. (n = 3). (Soffar et al., 2013). 
 
5.1.7 CDK2 Knockdown has no impact on Cell Cycle Distribution of 
unirradiated and irradiated SAS and FaDu Cell Cultures 
We showed that the absence of CDK2 in MEFs is associated with a significant 
induction of G2/M phase block after irradiation (Figure  5.3B). To address the possible role 
of CDK2 in cell cycling of SAS and FaDu cancer cells upon irradiation, we performed cell 
cycle analysis. 
First, we investigated the effect of irradiation as monotherapy on the cell cycle of 
SAS and FaDu cell cultures. In this experiment, we analysed cell cycle distributions of 
unirradiated and 6 Gy-irradiated cell cultures. Our results revealed a typical radiation-
induced G2/M cell cycle phase arrest that peaks at approximately 14 h after irradiation in 
both cell lines (the differences between irradiated and unirradiated data points were 
statistically significant (P < 0.05) at 10, 14 and 18 h after irradiation) (Figure  5.9). In 
parallel, we observed a significant (P < 0.05) decrease in the G1 and S phase cell 
populations in both cell lines. These data suggest that the appropriate time point to 
conduct further cell cycle distribution analysis after irradiation is 14 h (Soffar et al., 2013). 
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Figure  5.9. Irradiation induces G2/M cell cycle arrest in SAS and FaDu cell cultures. SAS 
and FaDu cells were plated and after 72 h were irradiated with X-rays (0 or 6 Gy, single dose). 
Cells were pulse-labelled with BrdU at indicated time points and fixed. Cell nuclei were 
extracted, immunostained with anti-BrdU/FITC and counterstained with PI. Results show mean 
± s.d. (n = 3; student’s t-test; * P < 0.05; + P < 0.01). (Soffar et al., 2013). 
 
Next, we studied the effect of CDK2 knockdown as a single treatment (without 
irradiation) on the cell cycle distribution of SAS and FaDu cells. Our results showed 
unaffected cell cycle profiles after CDK2 knockdown as compared to controls (Figure 
 5.10) (Soffar et al., 2013). 
In order to investigate whether CDK2 knockdown affects the response of SAS and 
FaDu cell cycles to ionising radiation, we performed cell cycle analysis of CDK2 
knockdown and control cultures 14 h after irradiation (0 or 6 Gy, X-rays, single dose) as 
radiation-induced cell-cycle arrest in SAS and FaDu cells reaches the maximum at this 
time point (Figure  5.9). We observed that irradiation induces a typical G2/M cell cycle 
arrest in both cell lines (Figure  5.11), and that CDK2 knockdown did not modulate the cell 
cycle response to irradiation as compared to control cultures. 
Taken together, our results showed that neither CDK2 knockdown nor combined 
CDK2 knockdown plus irradiation results in any significant alteration in the cell cycle 
distribution of SAS and FaDu cell cultures. In contrast with our results in MEFs, these data 
suggest that CDK2 is dispensable for the cell cycle of SAS and FaDu cells (Soffar et al., 
2013). 
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Figure  5.10. CDK2 is dispensable for the cell cycle of SAS and FaDu cells. Cell cycle 
analysis of CDK2-depleted SAS and FaDu cell cultures as compared to controls. Cells were 
transfected with CDK2 siRNA#1 (non-specific siRNA was used as control). At indicated time 
points, cells were pulse-labelled with BrdU and fixed. Cell nuclei were extracted, 
immunostained with anti-BrdU/FITC and counterstained with PI (n = 3). (Soffar et al., 2013). 
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Figure  5.11. CDK2 is negligible for radiation-induced cell cycle arrest of SAS and FaDu 
cell cultures. Cell cycle analysis of unirradiated and 6 Gy-irradiated CDK2-depleted SAS and 
FaDu cell cultures as compared to controls. CDK2 siRNA#1-transfected and control cultures 
were irradiated with X-rays (0 or 6 Gy, single dose). After 14 h, cells were pulse-labelled with 
BrdU and fixed. Cell nuclei were extracted, immunostained with anti-BrdU/FITC and 
counterstained with PI. Results show mean ± s.d. (n = 3). (Soffar et al., 2013). 
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Next, we performed Western blot analysis to investigate the effect of CDK2 
knockdown on the expression and phosphorylation levels of a panel of CDK2 interacting 
partners. Densitometric analysis of Western blots of investigated proteins was performed 
using the ImageJ (Version 1.47g) software, and data were blotted as bar graphs. All data 
values were normalised to β-actin as loading control, and density values of 
phosphorylation levels of proteins were normalised to total protein levels. Our results 
showed a 2-fold induction in the expression of Cyclin D1 and a 1.3-fold induction in the 
level of p27 in CDK2 knockdown cell cultures as compared to control cultures (Figure 
 5.12). Moreover, the level of Cyclin E was significantly elevated in SAS but not FaDu cells. 
No critical changes were observed in the expression levels of Cyclin A, RPA and ORC1. 
Most importantly, CDK2 knockdown had no impact on the phosphorylation of Rb, the main 
downstream substrate of CDK2, in both tested cell lines indicating a possible 
compensatory pathway for CDK2 functions (Soffar et al., 2013). 
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Figure  5.12. Knockdown of CDK2 modulates cell cycle proteins in SAS and FaDu cells. 
Western blot analysis of protein lysates of CDK2 siRNA#1-transfected SAS and FaDu cell 
cultures (non-specific siRNA was used as control) harvested 48 h after transfection. β-actin 
served as loading control. Bar graphs: Densitometric analysis displays the fold change of 
expression and phosphorylation of proteins after CDK2 knockdown relative to control. Results 
show mean ± s.d. (n = 3; student’s t-test; * P < 0.05; + P < 0.01). (Soffar et al., 2013). 
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5.1.8 CDK2 Knockdown does not affect the Radiosensitivity of SAS 
and FaDu cells under 3D Growth Conditions 
3D lrECM-based cell culture model better mimics the physiological growth 
conditions as compared to the traditional 2D monolayer culture (Eke et al., 2013). 
Therefore, we performed 3D lrECM colony formation assays to evaluate the clonogenic 
radiation survival of CDK2 knockdown and control SAS and FaDu cell cultures under 3D 
growth conditions. Our results showed that CDK2 knockdown (Figure  5.13A) has neither a 
significant effect on basal clonogenic survival (Figure  5.13B, C) nor on clonogenic 
radiation survival of SAS and FaDu cell cultures (Figure  5.13C, D) (Soffar et al., 2013). 
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Figure  5.13. CDK2 knockdown does not impact the radiosensitivity of SAS and FaDu cell 
cultures under 3D growth conditions. CDK2 siRNA#1-transfected and control cultures were 
plated under 3D lrECM growth condition for colony formation assays. After 24, cells were 
irradiated with X-rays (0 - 8 Gy, single dose). After a certain incubation time (SAS: 7 days, 
FaDu: 9 days), formed colonies were microscopically counted. (A) CDK2 Western blot of CDK2 
knockdown and control whole cell lysates. β-actin served as loading control. (B) 
Representative photographs show SAS and FaDu 3D colony formation assays after CDK2 
knockdown plus/minus irradiation. Bar, 200 μm. (C) Basal survival fraction of 3D SAS and 
FaDu CDK2-depleted or control cell cultures. Results show mean ± s.d. (n = 3; student’s t-test; 
n.s. not significant). (D) 3D colony formation of CDK2 knockdown or control SAS and FaDu cell 
cultures irradiated with X-rays (0 - 8 Gy, single dose). Results show mean ± s.d. (n = 3; 
student’s t-test; n.s. not significant). (Soffar et al., 2013). 
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5.2 CDK9 regulates the Radiosensitivity, DNA Damage 
Repair and Cell Cycle of HNSCC Cancer Cells 
Recently, Yu and colleagues reported that CDK9 plays a role in maintaining the 
genomic integrity in response to replication stress and promotes recovery from replication 
arrest (Yu et al., 2010). Such functions are necessary for cancer cell survival after 
radiation-induced genomic damage. Here, we investigated the potential role of CDK9 in 
the response of human HNSCC cancer cells to ionising radiation. 
5.2.1 CDK9 Knockdown renders HNSCC Cells more radiosensitive 
to X-rays 
To evaluate the role of CDK9 in the cellular radiation response, we investigated the 
clonogenic radiation survival upon CDK9 knockdown in a panel of 5 HNSCC cell lines 
using 2D colony formation assays. The investigated cell lines were SAS, FaDu, Cal33, 
HSC4 and UTSCC5. CDK9 knockdown was performed using two different CDK9 siRNAs 
(CDK9 siRNA#1, CDK9 siRNA#2). Non-specific siRNA was used as control. Our results 
showed that CDK9 siRNA-mediated knockdown results in an efficient reduction in the 
expression level of CDK9 in all cell lines (Figure  5.14A) except Cal33, in which CDK9 
siRNA#1-mediated knockdown failed. As compared to controls, we observed unaffected 
basal survival fraction after CDK9 knockdown in all cell lines except SAS, in which the 
CDK9 knockdown significantly (P < 0.05) decreases the basal clonogenic survival (Figure 
 5.14B). Interestingly, CDK9 knockdown significantly decreased the radiosensitivity of all 
tested cell lines to ionising radiation as compared to controls (an exception was CDK9 
siRNA#1-depleted UTSCC5 cell cultures) (Figure  5.14C). These results suggest a critical 
role for CDK9 in the clonogenic cell survival of investigated HNSCC cell lines upon 
irradiation. 
Our further investigations to evaluate the role of CDK9 for radiation response were 
performed using CDK9 siRNA#1-depleted SAS and FaDu cell cultures. 
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Figure  5.14. CDK9 knockdown modulates the sensitivity of HNSCC cancer cells to X-
rays. Cells were transfected (CDK9 siRNA #1, CDK9 siRNA #2; Co siRNA) and plated for 
colony formation. After 24 h, the plated cells were irradiated with X-rays (0 - 8 Gy, single dose). 
Formed colonies were counted after 7 - 14 days (cell line dependent). (A) Efficient CDK9 
depletion was confirmed by Western blotting. β-actin served as loading control. (B) Basal 
survival fraction after CDK9 knockdown. Results show mean ± s.d. (n = 3; student’s t-test; n.s. 
not significant; * P < 0.05). (C) Clonogenic survival of indicated HNSCC cell lines upon CDK9 
knockdown. Results show mean ± s.d. (n = 3; student’s t-test; * P < 0.05; + P < 0.01). 
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5.2.2 Depletion of CDK9 contributes to Repair of radiation-induced 
DSBs in SAS and FaDu cells 
Ionising radiation targets DNA and induces DNA damage (Hall & Giaccia, 2006; 
Han & Yu, 2010). A serious form of radiation-induced DNA damage is DSB which, if not 
properly repaired, may kill the cell (Shaheen et al., 2011; Symington & Gautier, 2011). In 
order to investigate whether CDK9 is involved in DNA damage repair of DSBs, we 
performed γH2AX/53BP1 foci assay to evaluate the number of radiogenic residual DSBs 
in CDK9-depleted and control SAS and FaDu cell cultures (Figure  5.15A). Our results 
displayed a significant (P < 0.05) increase in the number of residual DSBs in irradiated 
cells upon CDK9 silencing (Figure  5.15B). 
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Figure  5.15. CDK9 silencing increases the number of radiation-induced residual DNA 
DSBs. CDK9 siRNA#1-transfected cells (non-specific siRNA was used as control) were 
irradiated with X-rays (0 or 6 Gy, single dose). After 24 h, cells were fixed and immunostained 
against γH2AX and 53BP1. DAPI was used to stain nuclei. Double stained foci from 50 cell 
nuclei were counted by a fluorescence microscope and defined as residual DSBs. (A) 
Representative images show γH2AX/53BP1 double staining of unirradiated and irradiated 
CDK9-depleted and control cultures. γH2AX (red), 53BP1 (green), DAPI (blue). Bar, 10 μm. (B) 
Number of γH2AX/53BP1-positive foci per cell of CDK9 knockdown SAS and FaDu cells as 
compared to controls. Results show mean ± s.d. (n = 3; student’s t-test; * P < 0.05). 
 
To better understand the role of CDK9 in DNA damage repair, we investigated the 
effect of CDK9 knockdown on the checkpoint signalling and DNA damage repair proteins 
by Western blotting. In this experiment, we prepared total cell lysates of CDK9 knockdown 
and control cultures 15 min after irradiation (0 or 6 Gy, X-rays, single dose). Densitometric 
analysis of Western blot signals of investigated proteins was performed using the ImageJ 
(Version 1.47g) software, and data were blotted as bar graphs in Figure  5.16B. All 
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measured data values were normalised to β-actin as loading control, and values of 
phosphorylation levels of proteins were normalised to total protein levels. We did not 
observe considerable differences in expression and phosphorylation levels of the 
investigated proteins including ATM, phospho-ATM(S1981), DNA-PK, CHK2, phospho-
CHK2(T86), RAD50, NBS1 and PCNA upon CDK9 knockdown in both non-irradiated and 
irradiated SAS and FaDu cell cultures (Figure  5.16A, B). These results cannot explain the 
molecular role of CDK9 in DNA damage repair. 
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Figure  5.16. Effect of CDK9 depletion on DNA damage repair proteins. (A) Whole cell 
protein lysates of CDK9 siRNA#1-transfected cell cultures (non-specific siRNA was used as 
control) harvested 15 min after irradiation (0 or 6 Gy, X-rays, single dose) and analysed by 
SDS-PAGE and Western blotting. β-actin served as loading control. (B) Densitometric values 
of Western blots of Figure A. Data were normalised to β-actin. Results show mean ± s.d. (n = 
2; student’s t-test; + P < 0.01). 
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5.2.3 CDK9 silencing does not impact Apoptosis in SAS and FaDu 
Cells 
Serious DNA damage, such as DSBs, may induce cell death by activating 
apoptosis (Ciccia & Elledge, 2010). Because of the increased number of radiogenic 
residual DSBs upon CDK9 knockdown, we performed apoptosis assay to evaluate 
whether CDK9 modulates the radiation-induced apoptosis in SAS and FaDu cells. Our 
results showed very low level of apoptosis in unirradiated as well as irradiated SAS and 
FaDu control cell cultures. Moreover, we observed that CDK9 depletion has no significant 
impact on apoptosis in both unirradiated and irradiated cell cultures (Figure  5.17). 
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Figure  5.17. Apoptosis in unirradiated and irradiated CDK9 knockdown or control SAS 
and FaDu cell cultures. CDK9 siRNA#1-transfected cells (non-specific siRNA was used as 
control) were irradiated with X-rays (0 or 6 Gy, single dose). After 24 h, cells were fixed and 
stained with DAPI. The number of apoptotic nuclei per 100 cells was counted using a 
fluorescence microscope. Results show mean ± s.d. (n = 3). 
 
5.2.4 Depletion of CDK9 modulates Cell Cycling in SAS and FaDu 
Cells 
In addition to its well-known role in transcription elongation (Loyer et al., 2005; 
Malumbres & Barbacid, 2005; Ramanathan et al., 2001; Romano & Giordano, 2008; Zhou 
et al., 2000), CDK9 is able to phosphorylate the Rb (Simone et al., 2002). The Rb is an 
important cell cycle regulator through which CDK9 might play a role in cell cycle 
regulation. Therefore, we performed a cell cycle analysis at different time points following 
CDK9 knockdown in SAS and FaDu cell cultures. Our data showed that CDK9 knockdown 
leads to a significant increase (P < 0.05) in the G1 phase population (Figure  5.18). In 
consequence, the S phase population was significantly (P < 0.05) decreased. No changes 
were observed in the G2/M phase population. 
In order to investigate whether CDK9 knockdown affects cell cycling in response to 
irradiation, we analysed the cell cycle of CDK9-depleted and control SAS and FaDu cell 
cultures 14 h after irradiation with X-rays (0 or 6 Gy, single dose).Our results showed that 
CDK9 knockdown has no impact on the cell cycle distribution of unirradiated as well as 6 
Gy-irradiated SAS and FaDu cell cultures as compared to controls (Figure  5.19). 
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Figure  5.18. Depletion of CDK9 induces changes in cell cycles of SAS and FaDu cells. 
Cell cycle analysis of CDK9-depleted SAS and FaDu cell cultures as compared to controls. 
Cells were transfected with CDK9 siRNA#1 (non-specific siRNA was used as control). At 
indicated time points, cells were pulse-labelled with BrdU and fixed. Cell nuclei were extracted, 
immunostained with anti-BrdU/FITC and counterstained with PI. Results show mean ± s.d.     
(n = 3; student’s t-test; * P < 0.05; + P < 0.01). 
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Figure  5.19. CDK9 knockdown does not affect the radiation-induced cell cycle arrest in 
SAS and FaDu cell cultures. Cell cycle analysis of unirradiated and 6 Gy-irradiated CDK9-
depleted SAS and FaDu cell cultures as compared to controls. CDK9 siRNA#1-transfected and 
control cultures were irradiated with X-rays (0 or 6 Gy, single dose). After 14 h, cells were 
pulse-labelled with BrdU and fixed. Cell nuclei were extracted, immunostained with anti-
BrdU/FITC and counterstained with PI. Results show mean ± s.d. (n = 3; student’s t-test;          
* P < 0.05). 
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We next analysed the kinetic of expression and phosphorylation of a panel of cell 
cycle regulatory proteins as well as expression and phosphorylation of Rpb1-CTD of 
RNAPII upon CDK9 knockdown using Western blotting (Figure  5.20A). Densitometric 
analysis of Western blot signals of investigated proteins was performed using the ImageJ 
(Version 1.47g) software, and data were blotted as graphs in Figure  5.20B. All measured 
data values were normalised to β-actin as loading control, and values of phosphorylation 
levels of proteins were normalised to total protein levels. In parallel with the depletion of 
CDK9, we observed a rapid decline in the level of Cyclin D1, an induction in the level of 
Cyclin E and a slight reduction in the phosphorylation of Rb at residue S795 as compared 
to controls in both SAS and FaDu cell lines. However, no changes were observed on the 
levels of Rb, Rpb1-CTD or phospho-Rpb1-CTD(S2/5). These data suggests that CDK9 
plays a role in the regulation of cell cycling in SAS and FaDu cell lines. 
5.2.5 Characterisation of SAS-CDK9-EGFP and SAS-EGFP 
Transfectants 
We showed that CDK9 knockdown is associated with increased radiosensitivity in 
SAS, FaDu, HSC4, Cal33 and UTSCC5 HNSCC cell lines (Figure  5.14). To better 
understand the possible role of CDK9 in the radiation response of cancer cells, we 
generated a SAS-CDK9-EGFP cell line by stable transfection of SAS cells with the 
hCDK9-pEGFP-N1 plasmid. Empty vector (pEGFP-N1) stably transfected cells (SAS-
EGFP) were also generated and used as control. 
To confirm CDK9-EGFP and EGFP expression, SAS-CDK9-EGFP and SAS-EGFP 
cell lines were subjected to microscopic analysis (Figure  5.21A). In addition, Western blot 
analysis showed that SAS-CDK9-EGFP cells express both the exogenous CDK9-EGFP 
fusion protein as well as the endogenous CDK9 protein (Figure  5.21B). 
5.2.6 Ectopic Expression of CDK9 leads to radioresistance in SAS 
Cells 
To better understand the role of CDK9 in the cellular radiation response, we 
performed colony formation assays using SAS-CDK9-EGFP cells (SAS-EGFP cells were 
used as control) to evaluate the effect of ectopic overexpression of CDK9 on the 
clonogenic radiation survival. Our results showed that exogenous expression of CDK9-
EGFP in SAS cells is associated with a significantly (P < 0.05) increased basal survival 
(Figure  5.22A) as well as a significant (P < 0.05) increase in the clonogenic radiation 
survival of cells at high radiation dose (Figure  5.22B). 
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Figure  5.20. Protein analysis affirms a possible role for CDK9 on cell cycle regulation. 
CDK9 siRNA#1-transfected cell cultures (non-specific siRNA was used as control) were 
irradiated (0 or 6 Gy, X-rays, single dose), lysed in modified RIPA lysis buffer at indicated time 
points and analysed by SDS-PAGE and Western blotting. (A) Western blots for proteins 
regulate cell cycle and transcription. β-actin served as loading control. (B) Densitometric 
analysis of Western blots in Figure A. Data was normalised to 0 h values. Results show mean 
± s.d. (n = 3; student’s t-test; * P < 0.05; + P < 0.01).  
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Figure  5.21. Expression and localisation of CDK9-EGFP in SAS transfectants. SAS-
CDK9-EGFP and SAS-EGFP cells were generated by stable transfection of SAS cells with 
hCDK9-pEGFP-N1 or pEGFP-N1 plasmids respectively. (A) Fluorescence images of EGFP 
and CDK9-EGFP (green) expressing cells. Cell nuclei were stained with DAPI (blue). Bar, 20 
μm. (B) Western blots of EGFP and CDK9 in EGFP and CDK9-EGFP transfectants. β-actin 
served as loading control. 
 
B
Su
rv
iv
in
g 
fra
ct
io
n
Radiation dose [Gy]
0 2 4 6 8
0.001
0.01
0.1
1
*
0.0
0.4
0.8
1.2
1.6
*
A
Su
rv
iv
in
g 
fra
ct
io
n
SAS-EGFP
SAS-CDK9-EGFP SAS-EGFP
SAS-CDK9-EGFP
 
Figure  5.22. Exogenous expression of CDK9 induces radioresistance in SAS cells. SAS-
CDK9-EGFP and SAS-EGFP (as control) transfectants were plated for colony formation and 
irradiated after 24 h with X-rays (0 - 8 Gy, single dose). After 7 days, formed colonies were 
microscopically counted. (A) Basal survival fraction of unirradiated cell cultures. Results show 
mean ± s.d. (n = 3; student’s t-test; * P < 0.05). (B) Clonogenic radiation survival of SAS-
CDK9-EGFP and SAS-EGFP cells. Results show mean ± s.d. (n = 3; student’s t-test; * P < 
0.05). 
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6 Discussion 
Among other hallmarks (Hanahan & Weinberg, 2011), tumour cells are 
characterised by uncontrolled proliferation resulting from mutations in proto-oncogenes or 
tumour suppressor genes as well as environmental factors (Baumann et al., 2008; 
Burkhart & Sage, 2008; Finlay et al., 1989; Hahn & Weinberg, 2002; Hanahan & 
Weinberg, 2000; Hanahan & Weinberg, 2011; Jacks & Weinberg, 2002; Karnoub & 
Weinberg, 2008; Lodish et al., 2000b; Lu et al., 2012; Sandfort et al., 2007; Vogelstein & 
Kinzler, 2004). This allows cancer cells to escape cell death in response to potentially 
lethal damage and renders cells more resistant to standard cancer treatments such as 
radio- and chemotherapies (Hanahan & Weinberg, 2000; Johnstone et al., 2002). 
Disregulated activity of CDKs is common in many human cancers (Malumbres & 
Barbacid, 2001; Malumbres & Barbacid, 2009). Therefore, CDKs are regarded as 
potential targets for cancer therapy. 
6.1 CDK2 Targeting enhances the Radiosensitivity of HNSCC 
Cancer Cells 
CDK2 regulates important cellular events such as the G1/S phase transition, S 
phase progression, cell cycle checkpoints and apoptosis (Aleem et al., 2004; Deans et al., 
2006; Kaldis & Aleem, 2005; Neganova et al., 2011; Satyanarayana & Kaldis, 2009b; 
Sherr & Roberts, 2004; Soffar et al., 2013). In addition, overexpression of CDK2 was 
found to be correlated with poorer prognosis and overall survival in head and neck 
cancers (Dong et al., 2001; Mihara et al., 2001; Shintani et al., 2002), ovarian cancer (Sui 
et al., 2001) and melanoma (Tang et al., 1999). Therefore, understanding the possible 
role of CDK2 in radiation response might be of utmost importance for advancement of 
anticancer therapies. In this study, we evaluated the significance of CDK2 for the cellular 
radiation response of MEFs as well as HNSCC cell lines (SAS, FaDu, HSC4, Cal33, 
UTSCC5 and UTSCC8). In order to address the role of CDK2, we performed a series of 
experiments to measure several key parameters such as clonogenic radiation survival, 
DNA damage repair, apoptosis and cell cycling (Soffar et al., 2013). 
 
We showed that: 
1. CDK2 deficiency is associated with increased cellular radiosensitivity in MEFs. 
2. Loss of CDK2 in MEFs attenuates radiogenic DSBs repair. 
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3. CDK2 deficiency in MEFs correlates with higher radiation-induced G2/M arrest. 
4. CDK2 knockdown enhances the radiosensitivity of 2D HNSCC cell cultures. 
5. Silencing of CDK2 curbs radiogenic DSB repair in SAS and FaDu cells. 
6. Depletion of CDK2 does not affect apoptosis in 0 and 6 Gy-irradiated SAS and 
FaDu cell cultures. 
7. CDK2 knockdown has no impact on cell cycle distribution of unirradiated as well 
as irradiated SAS and FaDu cell cultures. 
8. Silencing of CDK2 does not alter the radiosensitivity of SAS and FaDu cell 
cultures under 3D growth conditions. 
 
Our results from the colony formation assays showed that loss of CDK2 is 
associated with increased cellular radiosensitivity of MEFs. In accordance, Satyanarayana 
and colleagues reported increased radiosensitivity in CDK2-/- mice relative to WT mice 
(Satyanarayana et al., 2008). A possible key factor in the cellular radiation survival is the 
efficiency of DNA damage repair (Chavaudra et al., 2004; Hedman, 2012). Therefore, we 
investigated the number of radiogenic residual DSBs, and found that CDK2-/- MEFs 
accumulates more radiogenic residual DSBs as compared to WT MEFs. These findings 
suggest a possible role of CDK2 in DNA damage repair of DSBs. Similar findings were 
reported by Satyanarayana and colleagues (Satyanarayana et al., 2008). In addition, a 
recent study suggested that treatment of A549 cells with R-Roscovitine, a small molecule 
CDK inhibitor, decreases their ability to repair DNA damage in a CDK2-dependent manner 
(Federico et al., 2010). Furthermore, Müller-Tidow and colleagues reported that Cyclin A1 
plays a CDK2-mediated role in DSB repair (Muller-Tidow et al., 2004). 
Another possible factor that might affect cellular radiation survival of cells is cell 
cycling and cell cycle checkpoint regulation. Our cell cycle profiles revealed a higher S 
phase population in CDK2-/- MEFs as compared to WT MEFs suggesting compromised S 
phase progression or S/G2 phase transition. In addition, our results showed a rapid 
radiation-induced G2/M arrest in both CDK2-/- and WT MEFs that peaks 10 h after 
irradiation. However, 24 h after irradiation, both CDK2-/- and WT MEFs displayed a slight 
increase in the G1 phase population which probably resulted from the release of cells 
from the G2/M arrest. Interestingly, comparing the cell cycle profiles of CDK2-/- MEFs to 
WT MEFs 10 h after irradiation revealed that the absence of CDK2 contributes to higher 
accumulation of cells in the G2/M phase. The increase in G2/M phase population in 
response to ionising radiation together with the elevated number of radiogenic residual 
DSBs in CDK2-/- MEFs as compared to WT MEFs suggest a possible disruption of DNA 
damage repair capacity in the absence of CDK2 (Satyanarayana et al., 2008). 
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Taken together, our findings suggest that CDK2 contributes to increased 
radiosensitivity of MEFs via modulating DNA damage repair and G2/M checkpoint 
response. 
Based on our finding in MEFs, we hypothesised that CDK2 targeting improves 
cancer cell response to radiotherapy. Therefore, we investigated CDK2 as a potential 
cancer target in human HNSCC cell lines. In 2D colony formation assays, depletion of 
CDK2 clearly enhanced the radiosensitivity of SAS and FaDu cell lines. The other tested 
four HNSCC cell lines showed a non-significant radiosensitising trend upon CDK2 
depletion. Concurrently, knockdown of CDK2 increased the number of radiation-induced 
residual DSBs in comparison to controls, which indicates a possible role of CDK2 in DNA 
damage repair in SAS and FaDu HNSCC cancer cells. Similarly, previous studies 
suggested that DSB repair function depends on CDK2 activity (Muller-Tidow et al., 2004; 
Satyanarayana et al., 2008). Moreover, recent reports indicated that CDK2 is a specific 
requirement for the DNA damage repair response, and that other CDKs, such as CDK1, 
might be unable to compensate the DNA repair functions of CDK2 in human cells 
(Satyanarayana & Kaldis, 2009b; Wohlbold et al., 2012). Despite elevated DSB levels, we 
did not observe a clear impact of CDK2 depletion on the expression and phosphorylation 
levels of DNA damage repair proteins. These results cannot explain how CDK2 mediates 
DNA damage repair and further studies are warranted to clarify this issue. Several studies 
reported a possible role of CDK2 in promoting apoptosis (Berthet et al., 2007; Hiromura et 
al., 2002; Maddika et al., 2008). However, we did not observe any signs of apoptosis as a 
consequence of CDK2 depletion in SAS and FaDu cancer cells. In accordance with our 
findings, Edamatsu and colleagues reported that treatment of CEM leukemic cells with 
Roscovitine does not induce apoptosis (Edamatsu et al., 2000). 
As a next step, we investigated the cell cycle regulation and checkpoint response 
upon CDK2 knockdown plus/minus irradiation. Despite the typical radiation-induced G2/M 
arrest of untreated SAS and FaDu cells, knockdown of CDK2, as a single treatment or in 
combination with irradiation, had no impact on the cell cycle profiles of unirradiated as well 
as irradiated SAS and FaDu cells. These results suggest that the activity of CDK2 is 
dispensable for cell cycle progression and radiation-induced cell cycle arrest in SAS and 
FaDu cell lines. However, these findings are in contrast to our results in MEFs suggesting 
that CDK2 plays a more prominent role in cell cycling of MEFs than in HNSCC cells. Also, 
the difference in gene inhibition should be taken into consideration with a complete and 
stable gene knockout in MEFs and an almost complete and transient knockdown in 
HNSCC cells. Additionally, other CDK/Cyclin complexes may have the ability to 
compensate for the absence of CDK2 particularly under knockdown conditions (Aleem et 
al., 2005; Berthet et al., 2003; Cai et al., 2006; Ortega et al., 2003). We revealed, in 
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Western blot protein analysis, elevated levels of Cyclin D1 (in both SAS and FaDu cells) 
and Cyclin E (in SAS cells) upon CDK2 silencing. Similarly, Cai and colleageous reported 
an elevated Cyclin D level in NCI-H1299 and UTOS clones engineered to constitutively 
express CDK2 shRNA. Moreover, these clones also showed no apparent change in cell 
cycling (Cai et al., 2006). The elevated levels of the CDK inhibitor p27 may be attributed to 
the decreased CDK2 activity upon knockdown of CDK2 (Lacher et al., 2010; Li et al., 
2011; Rodriguez-Ubreva et al., 2009). Intriguingly, no changes were observed in the 
phosphorylation of Rb protein, the main substrate of CDK2/Cyclin complexes, following 
knockdown of CDK2. This observation suggests a possible compensation of CDK2 kinase 
activity by other CDKs such as CDK1 which, in the absence of CDK2, is able to form 
complexes with Cyclin E and drive cells via the G1/S phase transition (Aleem et al., 2005; 
Kaldis & Aleem, 2005). CDK4 was also found to be able to phosphorylate the Rb even at 
CDK2 preferred phosphorylation sites (Tetsu & McCormick, 2003). Cyclin D1 binds to and 
activates CDK4 (Matsushime et al., 1994; Sherr, 1995; Sherr & Roberts, 2004). Therefore, 
the elevated Cyclin D1 and Cyclin E levels upon CDK2 knockdown might contribute to 
increased activities of CDK4 and CDK1 respectively that compensate for the absence of 
CDK2 activity (Aleem et al., 2005; Cai et al., 2006; Kaldis & Aleem, 2005; Tetsu & 
McCormick, 2003). 
In short, our results suggest that CDK2 is dispensable for cell cycle progression 
and radiation-induced checkpoint response in SAS and FaDu cells. Subsequently, the 
elevated CDK2 knockdown-mediated radiosensitivity in SAS and FaDu cells is probably 
related to the impaired DNA repair (Satyanarayana et al., 2008). 
Finally, we used a 3D lrECM based colony formation assay to stress the need of 
CDK2 for cellular radiation survival. This model is widely employed to investigate the 
possible role of cell-matrix interactions on the sensitivity of cancer cells to radio- and 
chemotherapy (Eke & Cordes, 2011; Eke et al., 2013; Hehlgans et al., 2012; Storch et al., 
2010; Zschenker et al., 2012). Importantly, several studies reported that 3D ECM based 
cell culture models better mimic in vivo growth conditions than conventional 2D cell culture 
systems (Cordes et al., unpublished data; Eke et al., 2013; Kenny et al., 2007; Cordes et 
al., unpublished data, Lee et al., 2007; Pampaloni et al., 2007; Storch et al., 2010; Xu et 
al., 2009). Intriguingly, depletion of CDK2 failed to modulate the radiation survival of SAS 
and FaDu cancer cells cultured in a more physiologically 3D microenvironment indicating 
a non-essential role of CDK2 in the cellular radiation response of cells under 3D growth 
conditions. Further studies are warranted to explain why CDK2 is dispensable for the 
radiation survival of cells under 3D growth condition. 
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6.2 CDK9 regulates the Radiosensitivity, DNA Damage 
Repair and Cell Cycle of HNSCC Cancer Cells 
DNA damage repair is the main priority of cells in response to genetic stress. The 
efficiency of DNA repair is crucial for the cellular response to genotoxic treatment such as 
radiotherapy. Recently, Yu and colleagues reported that CDK9 plays a role in maintaining 
the genomic integrity in response to replication stress and promotes recovery from 
replication arrest (Yu et al., 2010). Such functions are necessary for cancer cell survival 
after radiation-induced genomic damage. Therefore, we investigated the possible role of 
CDK9 in the radiation response of HNSCC cell lines via the measurement of key 
parameters such as clonogenic radiation survival, DNA damage repair, apoptosis and cell 
cycling. 
 
In this study, we displayed that: 
1. CDK9 knockdown mediates increased cellular radiosensitivity of HNSCC cancer 
cells. 
2. Depletion of CDK9 attenuates the repair of radiogenic DSBs in SAS and FaDu 
cells. 
3. Silencing of CDK9 has no impact on apoptosis in SAS and FaDu cells. 
4. Knockdown of CDK9 modulates cell cycling in SAS and FaDu cells. 
5. Ectopic CDK9 expression confers radioresistance in SAS cells. 
 
We showed that depletion of CDK9 radiosensitises HNSCC cancer cells in a cell 
line dependent manner. As DSBs are considered a key determinant of cell survival in 
response to genotoxic stress (Shaheen et al., 2011; Symington & Gautier, 2011), we 
investigated the number of radiogenic residual DSBs upon CDK9 knockdown. Our data 
showed that silencing of CDK9 perturbs the repair of radiation-induced residual DSBs in 
SAS and FaDu cells. This indicates a possible role of CDK9 in DNA damage repair which 
may correlates with the enhanced radiosensitivity of cells upon depletion of CDK9 (Eke et 
al., 2007; Morawska, 2012; Rothkamm & Lobrich, 2003).  
CDK9 is the catalytic part of pTEFb which stimulates transcription elongation by 
phosphorylating Rpb1-CTD of RNAPII (Loyer et al., 2005; Malumbres & Barbacid, 2005; 
Ramanathan et al., 2001; Romano & Giordano, 2008; Zhou et al., 2000). Previous studies 
reported a possible selective regulatory role of CDK9 on the expression of a restricted 
subset of genes instead of the expression of most genes by RNAPII (Garriga et al., 2010). 
Therefore, it is possible that CDK9 may specifically regulate one or more DNA damage 
response proteins. Consequently, we performed Western blot analysis in unirradiated and 
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irradiated CDK9-depleted and control SAS and FaDu cultures. We did not observe any 
critical changes in the expression or phosphorylation of DNA damage repair and 
checkpoint proteins. Our findings are in agreement with a previous study showed that 
depletion of CDK9 did not significantly upregulate or downregulate the DNA damage 
response genes in genome-wide expression analysis (Yu & Cortez, 2011). These findings 
cannot explain how CDK9 modulates the DNA damage repair of DSBs. Further 
investigations are required to clarify the role of CDK9 in DNA damage repair. Several 
studies suggested that CDK9 inhibition induces apoptosis in osteosarcoma, multiple 
myeloma and non-small cell lung cancer cells (Cai et al., 2006; Gojo et al., 2002). 
However, we could not observe any induction in apoptosis following CDK9 depletion in 
both SAS and FaDu HNSCC cells. 
Our cell cycle analysis revealed that depletion of CDK9 delays cell cycle transition, 
which was indicated by an elevated G1-phase and declined S phase cell population. 
Similarly, Cai and colleagues reported that reduction of CDK9 activity was associated with 
changes in cell cycle distribution that were consistent with cell cycle delay (Cai et al., 
2006). The S phase retardation after CDK9 silencing seems to be a consequence of the 
accumulation of cells in the G1 phase. Mammalian cells exhibit variation in their response 
to irradiation as they move through the cell cycle. Cells in the G2/M phase are the most 
radiosensitive while cells in the G1 phase show only moderate radiosensitivity (Sinclair & 
Morton, 1966). The S phase cell population is more radioresistant than cells in any other 
cell cycle phase (Sinclair & Morton, 1966). Accordingly, the retardation of S phase 
population might contribute to the enhanced radiosensitivity of cancer cells upon CDK9 
knockdown. 
On the molecular level, Rb is a known substrate for CDK9 (Simone et al., 2002). 
Therefore, it is not surprising that Rb was found to be hypophosphorylated after silencing 
of CDK9. In addition, CDK9 depletion was associated with a remarkable decrease in 
Cyclin D1 level in SAS and FaDu cells. Cyclin D1-dependent kinase activity promotes G1 
phase progression by phosphorylating and inactivating Rb (Kato et al., 1993; Lundberg & 
Weinberg, 1998; Weinberg, 1995). Thus, the reduction of Cyclin D1 level might also 
contribute to hypophsphrylation of Rb. Moreover, because of the central role of Rb in cell 
cycle progression especially during the G1 phase, the observed cell cycle changes (the 
elevated G1 phase and decreased S phase populations) after CDK9 knockdown seems to 
be attributed to the hypophosphorylation of Rb (Cai et al., 2006; Zhang et al., 2008). In 
contrary with Cyclin D1, the level of Cyclin E, another G1 phase Cyclin, was elevated after 
CDK9 depletion which probably is an attempt of the cell to tune the cell cycle disturbance 
in response to the suppression of Cyclin D1-dependent kinase activity (Bowe et al., 2002). 
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Despite the well-known role of CDK9 in phosphorylating the Rpb1-CTD of RNAPII 
on S2 and S5 residues (Loyer et al., 2005; Malumbres & Barbacid, 2005; Palancade & 
Bensaude, 2003; Ramanathan et al., 2001; Romano & Giordano, 2008; Zhou et al., 2000), 
we unexpectedly did not observe any changes in the phosphorylation of Rpb1-CTD (S2/5) 
after depletion of CDK9. Several reports revealed that other CDKs, such as CDK12 and 
CDK13, regulate the transcription elongation by phosphorylating the Rpb1-CTD 
(Bartkowiak et al., 2010; Blazek et al., 2011). This may explain why CDK9 was negligible 
for Rpb1-CTD phosphorylation but cannot explain the CDK9-related changes in 
expression of Cyclin D1 and Cyclin E. 
To better address the role of CDK9 in radiation response, we stably transfected 
SAS cells with CDK9-EGFP (hCDK9-pEGFP-N1 plasmid) or EGFP (pEGFP-N1 plasmid) 
constructs. Our results showed that ectopic expression of CDK9 confers radioresistance 
in SAS cells at high irradiation dose. This finding together with our previous findings upon 
CDK9 knockdown suggest a crucial role of CDK9 in the cellular response of HNSCC cells 
to ionising radiation. Further examinations are required to better understand this role on 
the molecular level and its consequences for DNA damage repair and cell cycle 
regulation. 
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7 Summary and Conclusion 
Here, we revealed the possible roles of CDK2 and CDK9 in the response of 
HNSCC cancer cells to radiotherapy. Due to the lack of highly selective pharmacological 
inhibitors against CDK2 and CDK9, we employed siRNA interference technology to 
achieve selective depletion of these proteins. In order to achieve our goal, we performed a 
series of experiments to measure several key parameters such as clonogenic radiation 
survival, DNA damage repair, apoptosis and cell cycling 
We found that loss of CDK2 radiosensitises MEFs as well as HNSCC 2D cell 
cultures. However, under more physiological 3D lrECM growth conditions, targeting of 
CDK2 failed to modulate the radiosensitivity of HNSCC cells. In addition, loss of CDK2 
attenuated the repair of radiogenic DSBs in MEFs as well as SAS and FaDu cells 
indicating a possible role of CDK2 in DNA damage repair. Moreover, we found that CDK2 
is dispensable for cell cycle and checkpoint regulation in SAS and FaDu cells. Taken 
together, these results suggest that targeting of CDK2 may not provide a therapeutic 
benefit to overcome HNSCC cell resistance to radiotherapy. 
We also showed that depletion of CDK9 clearly enhances the radiosensitivity of 
HNSCC 2D cultures. In addition, the ectopic expression of CDK9 had a radioprotective 
effect on SAS cells. These findings suggest a critical role of CDK9 in the radiation 
response of HNSCC cells. Moreover, our results indicate a possible role of CDK9 in the 
DNA damage repair response and cell cycling of HNSCC cells. Conclusively, targeting of 
CDK9 might be a viable strategy to overcome cancer cell resistance to radiotherapy. 
Future investigations are warranted to elucidate the role of CDK9 in cancer cell 
response to irradiation under 3D growth conditions and in vivo models, as well as other 
tumour entities. 
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